Artificial virus capsid
By modifying β-annular peptides with cancer-specific ligands and fluorine-containing groups, the viral capsids achieve targeted delivery to cancer cells, improving therapeutic efficacy.
Patent Information
- Application Number
- PCT/JP2026/017553
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-02
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing artificial viral capsids lack specificity for targeting cancer cells, limiting their effectiveness as delivery carriers for therapeutic agents.
Modifying a portion of the β-annular peptides constituting the viral capsid with cancer-specific ligands, such as cRGD peptide or folic acid, linked via a divalent linking group to the C-terminus, and optionally incorporating fluorine-containing groups for enhanced cell permeability.
The modified viral capsids exhibit enhanced specificity and uptake by cancer cells, making them effective carriers for targeted drug delivery.
Smart Images

Figure JPOXMLDOC01-APPB-C000001 
Figure JPOXMLDOC01-APPB-C000002 
Figure JPOXMLDOC01-APPB-C000003
Abstract
Description
Artificial viral capsid
[0001] The present invention relates to an artificial viral capsid modified with a ligand for a receptor specifically expressed on cancer cells. This application claims priority based on Japanese Patent Application No. 2025-077571 filed in Japan on 7 May 2025, Japanese Patent Application No. 2025-135480 filed in Japan on 15 August 2025, and Japanese Patent Application No. 2025-145400 filed in Japan on 2 September 2025, the contents of which are incorporated herein by reference.
[0002] A spherical artificial viral capsid can be created by in vitro self-assembling a β-annulus peptide derived from the protein that forms the dodecahedral internal skeleton of the tomato bushy stunt virus (TBSV) capsid (Non-Patent Documents 1-4). The β-annulus peptide is a peptide that is the smallest unit, 24 amino acids long, and corresponds to a part of the capsid protein, which consists of 388 amino acids. The β-annulus peptide spontaneously self-assembles in water to form a spherical, hollow nanocapsule, or artificial viral capsid, with a diameter of approximately 30-50 nm. In this nanocapsule, the β-annulus peptide faces its N-terminus inward and its C-terminus outward. It has been demonstrated that various substances can be encapsulated in this artificial viral capsid (either in the form of free molecules or in a form that binds to or interacts with the N-terminus of the β-annulus peptide). Such encapsulating materials are also called guests, and depending on the type of guest, the diameter of the artificial viral capsid may be slightly enlarged. It has also been demonstrated that by linking molecules such as gold nanoparticles, 20-nucleotide single-stranded DNA, coiled-coil forming peptides, human serum albumin, and ribonuclease S near the C-terminus of the β-annular peptide, an artificial viral capsid with an outer surface modified by these molecules can be formed. Furthermore, it has been reported that a modified artificial viral capsid obtained by self-assembling a nucleic acid aptamer having a length of 40 nucleotides or more linked to the C-terminus of the β-annular peptide can be efficiently and specifically delivered (for example, introduced into the interior of a specific target cell) via the aptamer portion (Patent Document 1).
[0003] On the other hand, compounds with polyfluoro structures are known to be stable and low-toxicity in vivo, and to be excellent at being taken up into cells and exiting endosomes. It has been reported that by utilizing this property, an artificial viral capsid with excellent cell membrane permeability can be obtained by self-assembling a β-annular peptide of TBSV modified with a peptide containing an amino acid residue in which a fluorine atom has been introduced into the side chain (Patent Document 2).
[0004] Japanese Patent Publication No. 2022-173834, International Publication No. 2024 / 228371
[0005] Chem. Commun., 2018, vol.54, p.8944.Bioconjugate Chem. 2019, vol.30, p.1636-1641.J. Org. Chem. 2020, vol.85, p.1668-1673.J Pept Sci. 2017, vol.23(7-8), p.636-643.Kostrzewa-Nowak et al., British Journal of Cancer, 2005, vol.93, p.89-97.
[0006] The present invention aims to provide an artificial viral capsid that is specifically taken up by cancer cells.
[0007] The present inventors have discovered that by using a β-annular peptide modified with a ligand for a receptor specifically expressed on cancer cells (hereinafter sometimes referred to as a "cancer-specific ligand") in an artificial viral capsid obtained by self-assembling β-annular peptides of TBSV, the cancer cell specificity of the artificial viral capsid obtained by self-assembling the β-annular peptide can be improved, thus completing the present invention.
[0008] In other words, the present invention includes the following embodiments: [1] An artificial viral capsid formed by the self-assembly of a plurality of subunits, wherein the subunit is a β-annular peptide of tomato bushy stunt virus, at least a portion of the subunits constituting the artificial viral capsid is a β-annular peptide modified with a ligand of a receptor specifically expressed on cancer cells, and the ligand-modified β-annular peptide has the ligand linked to its C-terminus via a bivalent linking group. [2] The artificial viral capsid of [1], wherein the ligand is a low molecular weight compound, a peptide, an antibody, or a sugar / sugar derivative. [3] The artificial viral capsid of [1] or [2], wherein the ligand is one or more selected from the group consisting of cRGD peptide, EGFR peptide, transferrin, mannose, GalNAc, folic acid, and an antibody. [4] An artificial viral capsid according to any of [1] to [3], wherein the ligand is one or more selected from the group consisting of folic acid and cRGD peptide. [5] An artificial viral capsid according to any of [1] to [4], wherein the ratio of the number of molecules of β-annular peptide modified with the ligand to the total number of molecules of β-annular peptide constituting the artificial viral capsid is 5 mol% or more. [6] An artificial viral capsid according to any of [1] to [5], further comprising a β-annular peptide modified with a fluorine-containing group or a long-chain group, wherein the β-annular peptide modified with a fluorine-containing group has a fluorine-containing peptide containing the fluorine-containing group linked to its terminus via a divalent linking group, and the β-annular peptide modified with a long-chain group has a long-chain modified peptide containing the long-chain group linked to its terminus via a divalent linking group, wherein the long-chain group is an alkyl group having 8 to 30 carbon atoms that is not substituted with a fluorine atom, or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of an alkyl group having 8 to 30 carbon atoms that is not substituted with a fluorine atom.[7] The artificial virus capsid of [6] wherein the fluorine-containing group is an alkyl group having 1 to 30 carbon atoms substituted with one or more fluorine atoms, or an alkyl group having 2 to 30 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms and one or more hydrogen atoms are substituted with fluorine atoms. [8] The artificial virus capsid of [7] wherein the fluorine-containing group is an alkyl group having 2 to 30 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms and one or more hydrogen atoms are substituted with fluorine atoms, and the ratio of the number of oxygen atoms to the number of fluorine atoms constituting the fluorine-containing group is 0.05 to 0.40. [9] The fluorine-containing group is of the following general formula (1).
[0009]
[0010] [In formula (1), R 11 R is an alkylene group having 1 to 6 carbon atoms, or a branched alkylene group having 1 to 6 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms of the side chain; 12 is an alkylene group having 1 to 6 carbon atoms, or a branched alkylene group having 1 to 6 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms of the side chain; n 1 n is an integer greater than or equal to 1; 1 If R is an integer greater than or equal to 2, there are multiple R 12 The groups may all be of the same type or may be different from each other; the black circles represent bonding. The group represented by ] is a group in which one or more hydrogen atoms are replaced by fluorine atoms, and the number of oxygen atoms constituting the fluorine-containing group is N O The number of fluorine atoms constituting the fluorine-containing group N F The artificial virus capsid of [7] or [8], wherein the value obtained by dividing by is 0.05 to 0.40.
[10] The fluorine-containing group is of the following general formula (E1)
[0011]
[0012] [In the formula, R 21is a fluorine atom, a perfluoroalkyl group having 1 to 6 carbon atoms, or a perfluoroalkyl group having 1 to 6 carbon atoms in which one or more ether-bonding oxygen atoms are introduced between carbon atoms; a1 is an integer of 1 or more; when a1 is an integer of 2 or more, a plurality of R 21 may all be the same type of group, or may be groups different from each other; R 31 and R 32 are each independently a fluorine atom, a hydrogen atom, a perfluoroalkyl group having 1 to 6 carbon atoms, or a perfluoroalkyl group having 1 to 6 carbon atoms in which one or more ether-bonding oxygen atoms are introduced between carbon atoms; b1 is an integer of 1 or more; when b1 is an integer of 2 or more, a plurality of R 31 and R 32The artificial viral capsid of [7] or [8], wherein the groups are all of the same kind or are all different from each other; the number of carbon atoms in the formula is 2 to 30; the ratio of oxygen atoms to fluorine atoms in the formula is 0.05 to 0.40; the black circles represent bonding hands.
[11] The artificial viral capsid of any of [6] to
[10] , wherein the fluorine-containing peptide is a peptide in which 1 to 3 of the fluorine-containing groups are directly or indirectly linked to the side chain of at least one amino acid residue.
[12] The artificial viral capsid of any of [1] to
[11] , wherein the divalent linking group is a Bis-maleimide group containing maleimide groups at both ends.
[13] The artificial viral capsid according to any of [1] to
[12] , wherein the β-annular peptide has a cysteine residue at or near its C-terminus, and the divalent linking group is linked to a thiol group derived from the cysteine residue.
[14] A method for producing an artificial viral capsid by self-assembling a raw material β-annular peptide in a solvent, wherein the raw material β-annular peptide contains a β-annular peptide modified with a ligand for a receptor specifically expressed on cancer cells, the ligand is linked to the C-terminus of the ligand-modified β-annular peptide via a divalent linking group, and the content ratio of the ligand-modified β-annular peptide to the total amount of the raw material β-annular peptide is 5 mol% or more.
[15] The β-annular peptide of the raw material further contains a β-annular peptide modified with a fluorine-containing group or a long-chain group, wherein the fluorine-containing group is an alkyl group having 1 to 30 carbon atoms substituted with one or more fluorine atoms, or an alkyl group having 2 to 30 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms and one or more hydrogen atoms are substituted with fluorine atoms, the long-chain group is an alkyl group having 8 to 30 carbon atoms not substituted with fluorine atoms, or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of an alkyl group having 8 to 30 carbon atoms not substituted with fluorine atoms, and the β-annular peptide modified with the fluorine-containing group has a fluorine-containing peptide containing the fluorine-containing group linked to the terminal of the β-annular peptide via a divalent linking group. A method for producing the artificial viral capsid of
[14] , wherein the β-annular peptide modified with the long-chain group has a long-chain modified peptide containing the long-chain group linked to its terminus via a divalent linking group.
[16] A method for producing the artificial viral capsid of
[14] or
[15] , wherein the content ratio of the β-annular peptide modified with the fluorine-containing group or the long-chain group to the total amount of the β-annular peptide of the raw material is 40 mol% or more.
[17] A pharmaceutical composition comprising the artificial viral capsid of any of [1] to
[13] .
[18] The pharmaceutical composition of
[17] for the treatment of cancer.
[19] A drug delivery carrier composition comprising the artificial viral capsid of any of [1] to
[13] .
[0013] The artificial viral capsid according to the present invention is modified with a cancer-specific ligand and therefore exhibits excellent specificity to cancer cells. For this reason, the artificial viral capsid is expected to be used in the pharmaceutical field as a delivery carrier (DDS carrier) for selectively transporting bioactive substances and drugs to cancer cells.
[0014] Reference Example 1 shows microscopic images of HeLa cells cultured in solution A (20 μM β-annulus, 5 μM TMR-β-annulus), solution B (25 μM TMR-PFE), solution C (25 μM TMR-β-annulus-PFE), or solution D (10 μM β-annulus, 10 μM β-annulus-PFE, 5 μM TMR-β-annulus). Reference Example 1 shows microscopic images of HepG2 cells cultured in solution A (20 μM β-annulus, 5 μM TMR-β-annulus), solution B (25 μM TMR-PFE), solution C (25 μM TMR-β-annulus-PFE), or solution D (10 μM β-annulus, 10 μM β-annulus-PFE, 5 μM TMR-β-annulus). Reference Example 4 shows a TEM image of a Dox-encapsulated viral capsid containing a PFE-modified β-annulus peptide formed in Reference Example 4. Reference Example 4 shows microscopic images of HepG2 cells that have taken up Dox (middle panel in the figure) and a Dox-encapsulated viral capsid containing a PFE-modified β-annulus peptide (bottom panel in the figure: DOX@capside). Reference Example 5 shows the results of measuring the particle size of viral capsids containing PFE-modified β-annulus peptides with different β-annulus-PFE content by DLS. Reference Example 5 shows the "Mean Count Rate" (average value of 10 count rate measurements in DLS) for each viral capsid. Reference Example 7 shows microscopic images of HepG2 cells cultured in a medium supplemented with mRNA-encapsulated PFE-modified β-annulus viral capsid, mRNA-encapsulated β-annulus viral capsid, Lipo-complexed mRNA, or mRNA alone. Reference Example 8 shows microscopic images of HepG2 cells cultured in solution A (20 μM β-annulus, 5 μM TMR-β-annulus) or solution B (10 μM β-annulus, 10 μM β-annulus-PFE2, 5 μM TMR-β-annulus). These are microscopic images of HeLa cells, HepG2 cells, and HEK293T cells cultured in a medium supplemented with the viral capsid of test group 8-4 in Example 1.These are microscopic images of HeLa cells, HepG2 cells, and HEK293T cells cultured in medium supplemented with the viral capsids of test groups 8-9 in Example 1. These are microscopic images of HepG2 cells cultured for 3 hours in solution A (45 μM β-annulus, 5 μM TMR-β-annulus) or solution B (45 μM β-annulus-cRGD, 5 μM TMR-β-annulus) in Example 2. These are microscopic images of HepG2 cells treated with anti-integrin antibody, cultured for 3 hours in solution A (45 μM β-annulus, 5 μM TMR-β-annulus) or solution B (45 μM β-annulus-cRGD, 5 μM TMR-β-annulus) in Example 2.
[0015] In the present invention and this specification, "C p1-p2 "(p1 and p2 are positive integers satisfying p1 < p2)" means that the group has between p1 and p2 carbon atoms.
[0016] In the present invention and this specification, "C 1-30 "Alkyl alkyl group" is an alkyl group having 1 to 30 carbon atoms, and may be a straight chain or a branched chain. 2-30 An alkyl group is an alkyl group having 2 to 30 carbon atoms, and may be a straight chain or a branched chain. 1-30 Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl, tetracosyl, pentacosyl, hexacosyl, heptacosyl, octacosyl, nonacosyl, and triacontyl groups.
[0017] In the present invention and this specification, "C 1-10 "Alkyl alkyl group" is an alkyl group having 1 to 10 carbon atoms, and may be a straight chain or a branched chain. 2-10An alkyl group is an alkyl group having 2 to 10 carbon atoms, and may be a straight chain or a branched chain. 1-10 Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, and decyl groups.
[0018] In the present invention and this specification, "C 1-6 An alkyl group is an alkyl group having 1 to 6 carbon atoms, and may be a straight chain or a branched chain. 1-6 Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl groups.
[0019] In the present invention and this specification, "C 8-30 An alkyl group is an alkyl group having 8 to 30 carbon atoms, and may be a straight chain or a branched chain. 8-30 Examples of alkyl groups include octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, heneicosyl, docosyl, tricosyl, tetracosyl, pentacosyl, hexacosyl, heptacosyl, octacosyl, nonacosyl, and triacontyl groups.
[0020] In the present invention and this specification, "C 1-6 An alkylene group is an alkylene group having 1 to 6 carbon atoms, and may be a straight chain or a branched chain. 1-6 Examples of alkylene groups include methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene, isopentylene, neopentylene, and hexylene.
[0021] In the present invention and this specification, "C 6-14An "aryl group" is an aromatic hydrocarbon group having 6 to 14 carbon atoms. 6-12 An aryl group is particularly preferred. 6-14 Examples of aryl groups include phenyl, naphthyl, anthryl, and 9-fluorenyl groups, with the phenyl group being particularly preferred.
[0022] In the present invention and this specification, "C which may be substituted" 6-14 The "aryl group" is C 6-14 An aryl group is a group in which one or more hydrogen atoms, preferably one to three, bonded to the carbon atom of the aryl group are substituted with other functional groups. When there are two or more substituents, the substituents may be of the same type or different types. The substituents may be a nitro group, a halogen atom (fluorine atom, chlorine atom, bromine atom, or iodine atom), or C 1-6 alkyl group, C 1-6 Alkoxy group and methylenedioxy group (-O-CH 2 Examples include -O-). "C may be substituted." 6-14 Examples of "aryl groups" include phenyl group, naphthyl group, anthryl group, 4-nitrophenyl group, 4-methoxyphenyl group, 2,4-dimethoxyphenyl group, 3,4-dimethoxyphenyl group, 4-methylphenyl group, 2,6-dimethylphenyl group, 3-chlorophenyl group, and 1,3-benzodioxol-5-yl group.
[0023] In the present invention and this specification, "C 1-6 An "alkoxy group" is a carbon atom with 1 to 6 carbon atoms. 1-6 This refers to a group in which an oxygen atom is bonded to the end of an alkyl group. 1-6 The alkoxy group may be linear or branched. 1-6 Examples of alkoxy groups include methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy groups.
[0024] In the present invention and this specification, "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. "Halogen atom other than a fluorine atom" means a chlorine atom, a bromine atom, or an iodine atom. Examples of "halogen atoms other than a fluorine atom" are preferably chlorine atoms or bromine atoms, and chlorine atoms are particularly preferred.
[0025] In the present invention and this specification, "ether-bonded oxygen atom" refers to an oxygen atom that links carbon atoms together, and does not include oxygen atoms that are linked in series. An alkyl group with Nc carbon atoms (where Nc is an integer of 2 or more) may have a maximum of Nc-1 ether-bonded oxygen atoms.
[0026] Furthermore, in the following, "compound n" refers to the compound represented by formula (n).
[0027] The artificial viral capsid according to the present invention is an artificial viral capsid formed by the self-assembly of a plurality of subunits, wherein the subunits are β-annular peptides of TBSV, and at least a portion of the subunits constituting the artificial viral capsid is a β-annular peptide modified with a cancer-specific ligand (hereinafter sometimes referred to as "cancer-specific ligand-modified β-annular peptide"). By making a portion of the β-annular peptide constituting the artificial viral capsid a cancer-specific ligand-modified β-annular peptide, the directivity to specific cancer cells can be increased. For this reason, an artificial viral capsid containing a cancer-specific ligand-modified β-annular peptide is useful as a carrier for cancer therapeutics.
[0028] <β-Annular Peptide> The β-annular peptide of TBSV (hereinafter simply referred to as "β-annular peptide") is publicly known and has been reviewed in Non-Patent Literature 1. The β-annular peptide consists of an amino acid sequence represented by INHVGGTGGAIMAPVAVTRQLVGS (Sequence ID 1). Of the amino acid sequence of Sequence ID 1, the regions from positions 1 to 5, from positions 10 to 13, and from positions 17 to 22 are essential for the formation of an artificial viral capsid by self-assembly (hereinafter sometimes referred to as the "consensus sequence of β-annular peptide"), and are the smallest units capable of forming an artificial viral capsid by self-assembly in water.
[0029] The β-annular peptide used in the present invention and this specification is not particularly limited as long as it contains a consensus sequence of β-annular peptide and is capable of forming an artificial viral capsid by self-assembly in water. For example, it may be a peptide consisting only of the amino acid sequence represented by SEQ ID NO: 1, and the region of the amino acid sequence represented by SEQ ID NO: 1 other than the consensus sequence of β-annular peptide may be substituted with other amino acid residues, deleted, or have other amino acid residues or amino acid sequences added, to the extent that it does not inhibit the formation of the artificial viral capsid. Furthermore, an additional amino acid sequence may be added to the C-terminus and / or N-terminus of SEQ ID NO: 1.
[0030] Previous studies have shown that an artificial viral capsid can be formed even if further amino acid sequences are added to the C-terminus and / or N-terminus of SEQ ID NO: 1. In the present invention and this specification, the β-annular peptide may be a peptide consisting of an amino acid sequence in which, for example, 1 to 20 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids are added to the N-terminus and / or C-terminus of the amino acid sequence represented by SEQ ID NO: 1.
[0031] The amino acid sequence added to the amino acid sequence represented by Sequence ID No. 1 is not particularly limited as long as it does not inhibit the formation of an artificial viral capsid by self-assembly. For example, it may be a linker sequence for linking to other substances that modify the β-annular peptide. Synthesizing a peptide such that a functional group useful for linker bonding or the linker itself is located at the N-terminus and / or C-terminus of the amino acid sequence represented by Sequence ID No. 1 is within the scope of the skill of those skilled in the art.
[0032] In the present invention and this specification, "subunit" refers to a unit molecule that forms an artificial viral capsid by self-assembly. Each subunit contains at least a β-annular peptide. However, multiple subunits that self-assemble into a single artificial viral capsid are not necessarily completely identical to each other. For example, a configuration in which subunits modified with fluorine-containing groups and subunits without fluorine-containing groups are mixed is also intended. An artificial viral capsid formed by the self-assembly of multiple subunits, each composed of subunits modified with different fluorine-containing groups, is also intended. Self-assembly refers to the phenomenon in which multiple β-annular peptide-containing subunits spontaneously combine in water or an aqueous solution to form a substantially spherical artificial viral capsid, as described in Non-Patent Documents 1 to 4, and the structure formed in this manner. The diameter of each artificial viral capsid formed by self-assembly (measured by DLS (dynamic light scattering)) may vary depending on the presence and type of guest, but is typically 30 to 300 nm. It is estimated that one artificial viral capsid contains approximately 60 subunits.
[0033] The β-annular peptides used in the present invention and this specification preferably have a cysteine residue at or near the C-terminus, specifically 1 to 5 amino acid residues from the C-terminus, and more preferably have a cysteine residue at 2 to 5 amino acid residues from the C-terminus. "1 amino acid residue from the C-terminus" refers to the amino acid residue at the C-terminus. Examples of β-annular peptides having a cysteine residue at or near the C-terminus include a peptide consisting of an amino acid sequence (INHVGGTGGAIMAPVAVTRQLVVCS: SEQ ID NO: 2) in which the second amino acid residue (G) from the C-terminus of SEQ ID NO: 1 is replaced with a cysteine residue, a peptide consisting of an amino acid sequence (INHVGGTGGAIMAPVAVTRQLVGC: SEQ ID NO: 3) in which the C-terminal amino acid residue (S) of SEQ ID NO: 1 is replaced with a cysteine residue, or a peptide consisting of an amino acid sequence in which a peptide of 1 to 4 amino acids is added to the C-terminal side of these amino acid sequences. Furthermore, the peptide may consist of an amino acid sequence in which an amino acid sequence consisting of 1 to 5 amino acids containing a cysteine residue is added to the C-terminus of the amino acid sequence of SEQ ID NO: 1. As for the amino acid sequence having a cysteine residue to be added to the C-terminus of the amino acid sequence of SEQ ID NO: 1, an amino acid sequence of 1 to 5 amino acids in which all but the cysteine residue are glycine residues is preferred, as it minimizes the impact on artificial viral capsid formation, and an amino acid sequence of 2 to 5 amino acids in which the second position from the C-terminus is a cysteine residue and all the others are glycine residues is more preferred.
[0034] The β-annular peptide used in the present invention and this specification may have a cysteine residue at or near its N-terminus, specifically, 1 to 5 amino acid residues from the N-terminus, and it is preferable that it has a cysteine residue at 1 amino acid residue from the N-terminus. Having a cysteine residue at or near its N-terminus makes it easy to modify the N-terminus of the β-annular peptide with other substances. An example of a β-annular peptide having a cysteine residue at or near its N-terminus is a peptide consisting of an amino acid sequence in which an amino acid sequence of 1 to 5 amino acids including a cysteine residue is added to the N-terminal side of the amino acid sequence of SEQ ID NO: 1. As for the amino acid sequence having a cysteine residue added to the N-terminal side of the amino acid sequence of SEQ ID NO: 1, an amino acid sequence of 1 to 5 amino acids in which all but the cysteine residue are glycine residues is preferred, in order to minimize the impact on artificial virus capsid formation, and an amino acid sequence of 2 to 5 amino acids in which the first residue from the N-terminus is a cysteine residue and all the others are glycine residues is more preferred.
[0035] <Cancer-Specific Ligands> Cancer-specific ligands are not particularly limited as long as they do not inhibit the formation of artificial viral capsids by the self-assembly of β-annular peptides, and can be appropriately selected from known cancer-specific ligands. Examples of cancer-specific ligands include antibodies (monoclonal antibodies, bispecific antibodies) such as anti-HER2 antibody, anti-CD20 antibody, anti-Ly6C antibody, anti-CD3 antibody, anti-CD4 antibody, anti-CD5 antibody, anti-CD7 antibody, anti-CD29 antibody, anti-CD31 antibody, anti-CD117 antibody, anti-CD140 antibody, anti-PDPN antibody, anti-PECAM-1 antibody, anti-PLVAP antibody, anti-VCAM-1 antibody, and bispecific antibodies using anti-PEG antibodies; hyaluronic acid, N-acetylgalactosin Examples include sugars and sugar derivatives such as mine (GalNAc) and mannose; low molecular weight compounds such as folic acid, PSMA ligand, strophanthidin, Glu-urea-Lys, and NAAG (N-acetyl-L-aspartyl-L-glutamic acid); peptides such as EGFR peptide, RGD peptide, cRGD peptide, CRV peptide, LDV peptide, Lyp-1 peptide, RWFV peptide, Epi-1 (Epinecidine-1) peptide, Cardiomyocyte-specific binding peptide, and Angiopep; proteins such as transferrin; and nucleic acids such as anti-PD-L1 DNA aptamers. The cancer-specific ligand that modifies the β-annular peptide constituting the artificial viral capsid according to the present invention is preferably one or more selected from the group consisting of low molecular weight compounds and peptides, more preferably one or more selected from the group consisting of cRGD peptide, EGFR peptide, transferrin, mannose, GalNAc, folic acid, and antibodies, and even more preferably one or more selected from the group consisting of folic acid and cRGD peptide.
[0036] <Divalent Linking Group> In the cancer-specific ligand-modified β-annular peptide, the cancer-specific ligand is linked to the C-terminus of the β-annular peptide via a divalent linking group. In the cancer-specific ligand-modified β-annular peptide of the artificial viral capsid according to the present invention, the divalent linking group that links the β-annular peptide and the cancer-specific ligand is not particularly limited as long as it is a divalent organic group. For example, alkylene group, oxygen atom (-O-), sulfur atom (-S-), -NH-, -N(CH) 3 )-,-N(C 2 H 5 )-,-N(C 3 H 7 )-, trivalent nitrogen atom, -C(=O)-, -S(=O) 2 - Examples include groups obtained by removing 2 to 4 hydrogen atoms from a cycloalkane, groups obtained by removing 2 to 4 hydrogen atoms from an aromatic ring (aryl group), groups obtained by removing 2 to 4 hydrogen atoms from a heterocycle (heteroaryl group), or combinations thereof. The groups listed above can be used as aryl groups and heteroaryl groups.
[0037] The divalent linking group of the artificial viral capsid according to the present invention is preferably a divalent group having at least one group that can selectively and readily bind to a thiol group, since it can readily bind to cysteine residues and the like. Examples of groups that can selectively and readily bind to a thiol group include maleimide groups, iodoacetyl groups, bromoacetyl groups, and pyridine disulfide. An example of such a divalent linking group is Bis-maleimide, which contains maleimide groups at both ends, as represented by the following general formula (3).
[0038]
[0039] In general formula (3), the black circles represent binding sites. Of the two black circles, one binds to the β-annular peptide, and the other binds to a group derived from the cancer-specific ligand. By utilizing the chemical reaction that forms a thioether group from a maleimide group and a thiol group, it is possible to easily bind to the thiol group of the cysteine residue in the β-annular peptide or to the thiol group in the group derived from the cancer-specific ligand. The reaction between the thiol group and the maleimide group can be carried out using commonly used organic synthesis reactions.
[0040] In general formula (3), Z 4 This consists of an alkylene group, an oxygen atom (-O-), a sulfur atom (-S-), -NH-, and -N(CH 3 )-,-N(C 2 H 5 )-,-N(C 3 H 7 )-, trivalent nitrogen atom, -C(=O)-, -S(=O) 2 - Examples include groups obtained by removing 2 to 4 hydrogen atoms from a cycloalkane, groups obtained by removing 2 to 4 hydrogen atoms from an aromatic ring (aryl group), groups obtained by removing 2 to 4 hydrogen atoms from a heterocycle (heteroaryl group), or combinations thereof. The groups listed above can be used as aryl groups and heteroaryl groups.
[0041] Z in general formula (3) 4 Examples include alkylene groups with 2 to 6 carbon atoms, -C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -O-C 2 H 4 -, -C 2 H 4 -O-C 2 H 4 -O-C 2H 4 -O-C 2 H 4 -O-C 2 H 4 -, -Ph-, -Ph-CH 2 -Ph-, -C(=O)-, -C(=O)-O-, -OC(=O)-, -NH-C(=O)-O-, -OC(=O)-NH-, -C(=O)-NH-, -NH-C(=O)-, -S(=O) 2 -NH-, -NH-S (=O) 2 -, -S (=O) 2 -NH-S (=O) 2 Examples include - and -C(=O)-NH-Ph-. Note that -Ph- is a 1,4-phenylene group, a 1,3-phenylene group, a 1,5-phenylene group, or a 1,3,5-substituted phenyl group.
[0042] <Cancer-Specific Ligand-Modified β-Annule Peptide> The cancer-specific ligand-modified β-annule peptide is obtained by linking the β-annule peptide and the cancer-specific ligand with a divalent linking group. The cancer-specific ligand may be linked to the N-terminus of the β-annule peptide, but it is preferable that it be linked to the C-terminus of the β-annule peptide via a divalent linking group. When the cancer-specific ligand is linked to the C-terminus of the β-annule peptide, the cancer-specific ligand is displayed on the outside of the hollow capsule of the artificial viral capsid.
[0043] The cancer-specific ligand-modified β-annular peptide in the artificial viral capsid according to the present invention may be one type or two or more types. For example, by using β-annular peptides modified with different cancer-specific ligands as raw materials, the artificial viral capsid according to the present invention can be made into an artificial viral capsid modified with two or more cancer-specific ligands.
[0044] The cancer-specific ligand-modified β-annular peptide of the artificial viral capsid according to the present invention may be bound to another substance at the end of the β-annular peptide that is not bound to the divalent linking group. The other substance is not particularly limited as long as it does not inhibit the formation of the artificial viral capsid by the self-assembly of the β-annular peptide, and examples include peptides, nucleic acids, small molecule compounds, and chimeric molecules consisting of two or more of these. For example, by binding poly(T)DNA to the end of the β-annular peptide that is not bound to the divalent linking group, the mRNA having a poly(A) tail and the cancer-specific ligand-modified β-annular peptide can be complexed, and an artificial viral capsid containing mRNA having a poly(A) tail can be efficiently formed. It is preferable to link the poly(T)DNA to the N-terminal side of the β-annular peptide. The N-terminal side of the β-annular peptide faces inward towards the artificial viral capsid. Therefore, by linking poly(T)DNA to the N-terminus of the β-annular peptide, mRNA with a poly(A) tail can be efficiently encapsulated in an artificial viral capsid.
[0045] <Fluorine-Modified β-Annular Peptide> The artificial viral capsid according to the present invention preferably also contains a fluorine-modified β-anular peptide (a β-anular peptide modified with a fluorine-containing group) in addition to the cancer-specific ligand-modified β-anular peptide. An artificial viral capsid containing both a fluorine-modified β-anular peptide and a cancer-specific ligand-modified β-anular peptide as the β-anular peptide constituting the artificial viral capsid can achieve both specific targeting of cancer cells and excellent cell permeability, thereby further enhancing its effectiveness as a cancer therapeutic agent.
[0046] Fluorine-modified β-annular peptides have a fluorine-containing peptide linked to the end of the β-annular peptide via a divalent linking group. The divalent linking group may be the same as those described in <Divalent Linking Group> above, and is preferably a group that can bind to a thiol. The divalent linking group linked to the fluorine-containing peptide can be linked to the N-terminal side of the β-annular peptide, but it is preferable that it be linked to the C-terminal side of the β-annular peptide. In artificial viral capsids of β-annular peptides, which are inherently hollow nanocapsules, the C-terminus of the β-annular peptide faces outward from the nanocapsule. Therefore, by linking the fluorine-containing peptide to the C-terminal side of the β-annular peptide, the fluorine-containing alkyl ether group in the fluorine-containing peptide can be presented on the surface of the artificial viral capsid, thereby more efficiently improving cell membrane permeability.
[0047] <Fluorine-containing group> At least a portion of the β-annular peptide constituting the artificial viral capsid according to the present invention may be a fluorine-modified β-annular peptide. The fluorine-containing group used to modify the β-annular peptide is not particularly limited. The fluorine-containing group in the fluorine-modified β-annular peptide constituting the artificial viral capsid according to the present invention may be an alkyl group having 1 to 30 carbon atoms substituted with one or more fluorine atoms (hereinafter sometimes referred to as "fluorine-containing alkyl group"), or C 2-30 A preferred group is one in which one or more ether-bonded oxygen atoms are introduced between carbon atoms of an alkyl group, and one or more hydrogen atoms are substituted with fluorine atoms (hereinafter sometimes referred to as a "fluorine-containing alkyl ether group").
[0048] When the fluorine-containing group used to modify the β-annular peptide is a fluorine-containing alkyl group, the fluorine-containing alkyl group may be linear or branched. Furthermore, the number of hydrogen atoms substituted for fluorine atoms is not particularly limited as long as it is one or more; for example, three or more are preferred, six or more are more preferred, and seven or more are even more preferred. The fluorine-containing alkyl group may be C 1-20A group in which one or more hydrogen atoms in an alkyl group are substituted with fluorine atoms is preferred, C 1-10 A group in which one or more hydrogen atoms in an alkyl group are substituted with fluorine atoms is more preferred. Specific examples of the fluorine-containing alkyl group include trifluoromethyl group, pentafluoroethyl group, heptafluoropropyl group, nonafluorobutyl group, perfluoropentyl group, perfluorohexyl group, perfluoroheptyl group, perfluorooctyl group, perfluorononyl group, perfluorodecyl group, difluoromethyl group, 1,1-difluoroethyl group, 2,2-difluoroethyl group, 1,1,2,2-tetrafluoroethyl group, 1,1,2,2,3,3-hexafluoropropyl group, 1,1,2,3,3,3-hexafluoropropyl group, 1,1,2,2,3,3-hexafluorohexyl group, 1,1,2,2,3,3-hexafluorooctyl group, 1,1,2,2,3,3-hexafluorodecyl group, 1,1,2,2,3,3-hexafluorooctadecyl group, 1,1,2,2,3,3-hexafluorohexacosyl group and the like.
[0049] When the fluorine-containing group used for modifying the β-annulus peptide is a fluorine-containing alkyl ether group, the fluorine-containing alkyl ether group used for modifying the β-annulus peptide may be a linear C 2-30 group obtained by introducing an ether-bonding oxygen atom and a fluorine atom into an alkyl group, or may be a branched C 2-30 group obtained by introducing an ether-bonding oxygen atom and a fluorine atom into an alkyl group. The fluorine-containing alkyl ether group may be a linear or branched C 2-20Groups in which an ether-bonded oxygen atom and a fluorine atom are introduced to an alkyl group are preferred, and groups in which an ether-bonded oxygen atom and a fluorine atom are introduced to an ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, tert-pentyl group, hexyl group, heptyl group, octyl group, nonyl group, decyl group, undecyl group, dodecyl group, tridecyl group, tetradecyl group, pentadecyl group, hexadecyl group, heptadecyl group, octadecyl group, nonadecyl group, eicosyl group, heneicosyl group, or docosyl group are more preferred.
[0050] The ether-bonded oxygen atoms of the fluorinated alkyl ether group used to modify the β-annular peptide may be one or more, preferably 1 to 5, more preferably 1 to 4, and even more preferably 1 to 3. The number of fluorine atoms of the fluorinated alkyl ether group is not particularly limited as long as it is one or more, for example, preferably 3 or more, more preferably 6 or more, and even more preferably 7 or more.
[0051] The number of oxygen atoms and fluorine atoms in a fluorine-containing alkyl ether group used to modify β-annular peptides is preferably in the range of 0.05 to 0.40, more preferably in the range of 0.05 to 0.35, more preferably in the range of 0.09 to 0.33, even more preferably in the range of 0.10 to 0.30, even more preferably in the range of 0.15 to 0.26, and particularly preferably in the range of 0.16 to 0.23, in order to improve the solubility of the fluorine-containing alkyl ether group and the cell membrane permeability of the artificial viral capsid modified with the fluorine-containing alkyl ether group.
[0052] Examples of fluorine-containing alkyl ether groups used to modify β-annular peptides include groups in which one or more hydrogen atoms in the group represented by the following general formula (1) are replaced with fluorine atoms. In general formula (1), black circles represent bonding bonds.
[0053]
[0054] In general formula (1), R 11 is a C 1-6 alkylene group, or a branched C in which one or more ether-bonding oxygen atoms are introduced between the carbon atoms in the side chain 1-6 alkylene group. R 11 is a C 1-6 alkylene group, it may be a linear alkylene group or a branched alkylene group. As R 11 , a linear or branched C 1-4 alkylene group is preferable, and a methylene group, ethylene group, propylene group or isopropylene group is more preferable. When R 11 is a branched C in which one or more ether-bonding oxygen atoms are introduced between the carbon atoms in the side chain 1-6 alkylene group, the alkyl group in the side chain is preferably a linear or branched C in which 1 to 3 ether-bonding oxygen atoms are introduced between carbon atoms 1-4 alkylene group.
[0055] In general formula (1), R 12 is a C 1-6 alkylene group, or a branched C in which one or more ether-bonding oxygen atoms are introduced between the carbon atoms in the side chain 1-6 alkylene group. R 12 is a C 1-6 alkylene group, it may be a linear alkylene group or a branched alkylene group. As R 12 , a linear or branched C 1-4 alkylene group is preferable, and a methylene group, ethylene group, propylene group or isopropylene group is more preferable. When R 12 is a branched C in which one or more ether-bonding oxygen atoms are introduced between the carbon atoms in the side chain 1-6 alkylene group, the alkyl group in the side chain is preferably a linear or branched C in which 1 to 3 ether-bonding oxygen atoms are introduced between carbon atoms 1-4 alkylene group.
[0056] In general formula (1), n1 n is an integer greater than or equal to 1. 1 Preferably, the values are 1 to 5, more preferably 1 to 4, even more preferably 1 to 3, and also preferably 1 or 2. 1 If R is an integer greater than or equal to 2, there are multiple R 12 These groups may all be of the same type, or they may be different from each other.
[0057] The preferred fluorine-containing alkyl ether group is one in which one or more hydrogen atoms in the group represented by general formula (1) are replaced with fluorine atoms. The number of fluorine atoms introduced by substitution is N. F This is the number of oxygen atoms N that make up the group represented by general formula (1). O to N F The value obtained by dividing by (N O / N F It is preferable that the value is designed to be within the range of 0.05 to 0.40, more preferably within the range of 0.05 to 0.38, 0.05 to 0.37, 0.05 to 0.35, and 0.09 to 0.33, even more preferably within the range of 0.10 to 0.30, even more preferably within the range of 0.15 to 0.26, and particularly preferably within the range of 0.16 to 0.23.
[0058] The preferred fluorine-containing alkyl ether group is one in which all hydrogen atoms in the group represented by general formula (1) are replaced with fluorine atoms. Hereafter, among the fluorine-containing alkyl ether groups, a group consisting only of carbon atoms, oxygen atoms, and fluorine atoms (a group in which all hydrogen atoms are replaced with fluorine atoms) may be referred to as a perfluoroalkyl ether group.
[0059] As the fluorine-containing alkyl ether group used for modifying β-annular peptides, a group represented by any of the following general formulas (E1) to (E8) is particularly preferred. In general formulas (E1) to (E8), black circles represent bonding bonds.
[0060]
[0061]
[0062] In general formula (E1), R 21 is a fluorine atom, or C1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 21 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 21 Examples include linear or branched C 1-4 Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 21 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 21 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0063] In general formula (E1), R 31 and R 32 These are, independently, a fluorine atom, a hydrogen atom, and C. 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 31 and R 32 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 31 and R 32 Examples include linear or branched C 1-4A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 31 and R 32 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 31 and R 32 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group (a perfluoromethyl group in which one ether-bonded oxygen atom is introduced between carbon atoms) or a perfluoromethoxymethyl group is even more preferred.
[0064] In the general formula (E1), a1 is an integer of 1 or more, preferably an integer from 1 to 10, more preferably an integer from 1 to 6, and even more preferably an integer from 1 to 4. When a1 is an integer of 2 or more, there are multiple R 21 The elements may all be of the same kind, or they may be different from each other. In the general formula (E1), b1 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b1 is an integer of 2 or more, there are multiple R 31 and R 32 These groups may all be of the same type, or they may be different from each other.
[0065] In general formula (E2), R 22 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 22 C 1-6If it is a perfluoroalkyl group, it may be a linear group or a branched group. 22 Examples include linear or branched C 1-4 Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 22 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 22 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0066] In general formula (E2), R 33 and R 34 These are, independently, a fluorine atom, a hydrogen atom, and C. 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 33 and R 34 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 33 and R 34 Examples include linear or branched C 1-4 A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 33 and R 34 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6If it is a perfluoroalkyl group, it may be a linear group or a branched group. 33 and R 34 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0067] In the general formula (E2), a2 is an integer of 1 or more, preferably an integer from 1 to 10, more preferably an integer from 1 to 6, and even more preferably an integer from 1 to 4. When a2 is an integer of 2 or more, there are multiple R 22 The elements may all be of the same kind, or they may be different from each other. In the general formula (E2), b2 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b2 is an integer of 2 or more, there are multiple R 33 and R 34 These groups may all be of the same type, or they may be different from each other.
[0068] In general formula (E2), R Pf C 1-6 It is a perfluoroalkyl group. PfExamples include trifluoromethyl group, pentafluoroethyl group, heptafluoropropyl group, nonafluorobutyl group, perfluoropentyl group, perfluorohexyl group, perfluoroheptyl group, perfluorooctyl group, perfluorononyl group, perfluorodecyl group, difluoromethyl group, 1,1-difluoroethyl group, 2,2-difluoroethyl group, 1,1,2,2-tetrafluoroethyl group, 1, Examples include 1,2,2,3,3-hexafluoropropyl group, 1,1,2,3,3,3-hexafluoropropyl group, 1,1,2,2,3,3-hexafluorohexyl group, 1,1,2,2,3,3-hexafluorooctyl group, 1,1,2,2,3,3-hexafluorodecyl group, 1,1,2,2,3,3-hexafluorooctadecyl group, and 1,1,2,2,3,3-hexafluorohexacosyl group.
[0069] In general formula (E3), R 23 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 23 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 23 Examples include linear or branched C 1-4 Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 23 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 23 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4Perfluoroalkyl groups are more preferred.
[0070] In general formula (E3), R 35 fluorine atom, hydrogen atom, C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 35 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 35 Examples include linear or branched C 1-4 A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 35 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 35 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0071] In the general formula (E3), a3 is an integer of 1 or more, preferably an integer from 1 to 10, more preferably an integer from 1 to 6, and even more preferably an integer from 1 to 4. When a3 is an integer of 2 or more, there are multiple R 23 The elements may all be of the same kind, or they may be different from each other. In the general formula (E3), b3 is an integer of 1 or more, preferably an integer from 1 to 5, more preferably an integer from 1 to 4, and even more preferably an integer from 1 to 3. When b3 is an integer of 2 or more, there are multiple R 35 These groups may all be of the same type, or they may be different from each other.
[0072] In general formula (E4), R 24 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 24 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 24 Examples include linear or branched C 1-4 Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 24 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 24 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0073] In general formula (E4), R 36 fluorine atom, hydrogen atom, C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 36 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 36 Examples include linear or branched C 1-4A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 36 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 36 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0074] In the general formula (E4), a4 is an integer of 1 or more, preferably an integer from 1 to 10, more preferably an integer from 1 to 6, and even more preferably an integer from 1 to 4. When a4 is an integer of 2 or more, there are multiple R 24 The elements may all be of the same kind, or they may be different from each other. In the general formula (E4), b4 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b4 is an integer of 2 or more, there are multiple R 36 These may all be the same type of group, or they may be different from each other. In general formula (E4), R Pf C 1-6 It is a perfluoroalkyl group. Pf For example, R in the general formula (E2) Pf Similar bases can be cited.
[0075] In general formula (E5), R 25 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 25 C 1-6If it is a perfluoroalkyl group, it may be a linear group or a branched group. 25 Examples include linear or branched C 1-4 Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 25 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 25 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0076] In general formula (E5), R 37 , R 38 and R 39 These are, independently, a fluorine atom, a hydrogen atom, and C. 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 37 , R 38 and R 39 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 37 , R 38 and R 39 Examples include linear or branched C 1-4 A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 37 , R 38 and R 39C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 37 , R 38 and R 39 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0077] In the general formula (E5), a5 is an integer of 1 or more, preferably an integer between 1 and 10, more preferably an integer between 1 and 6, and even more preferably an integer between 1 and 4. When a5 is an integer of 2 or more, there are multiple R 25 These may all be of the same kind, or they may be different from each other. In the general formula (E5), b5 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b5 is an integer of 2 or more, there are multiple R 37 , R 38 and R 39 These groups may all be of the same type, or they may be different from each other.
[0078] In general formula (E6), R 26 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 26 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 26 Examples include linear or branched C 1-4Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 26 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 26 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0079] In general formula (E6), R 40 , R 41 and R 42 These are, independently, a fluorine atom, a hydrogen atom, and C. 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 40 , R 41 and R 42 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 40 , R 41 and R 42 Examples include linear or branched C 1-4 A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 40 , R 41 and R 42 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 40 , R41 and R 42 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0080] In the general formula (E6), a6 is an integer of 1 or more, preferably an integer between 1 and 10, more preferably an integer between 1 and 6, and even more preferably an integer between 1 and 4. When a6 is an integer of 2 or more, there are multiple R 26 The elements may all be of the same kind, or they may be different from each other. In the general formula (E6), b6 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b6 is an integer of 2 or more, there are multiple R 40 , R 41 and R 42 These may all be the same type of group, or they may be different from each other. In general formula (E6), R Pf C 1-6 It is a perfluoroalkyl group. Pf For example, R in the general formula (E2) Pf Similar bases can be cited.
[0081] In general formula (E7), R 27 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 27 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 27 Examples include linear or branched C 1-4Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 27 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 27 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0082] In general formula (E7), R 43 , R 44 , R 45 , R 46 , and R 47 These are, independently, a fluorine atom, a hydrogen atom, and C. 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 43 , R 44 , R 45 , R 46 , and R 47 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 43 , R 44 , R 45 , R 46 , and R 47 Examples include linear or branched C 1-4 A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 43 , R 44 , R 45 , R 46, and R 47 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 43 , R 44 , R 45 , R 46 , and R 47 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0083] In the general formula (E7), a7 is an integer of 1 or more, preferably an integer from 1 to 10, more preferably an integer from 1 to 6, and even more preferably an integer from 1 to 4. When a7 is an integer of 2 or more, there are multiple R 27 The elements may all be of the same kind, or they may be different from each other. In the general formula (E7), b7 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b7 is an integer of 2 or more, there are multiple R 43 , R 44 , R 45 , R 46 , and R 47 These atoms may all be of the same type, or they may be different atoms from one another.
[0084] In general formula (E8), R 28 is a fluorine atom, or C 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 28 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 28 Examples include linear or branched C 1-4Perfluoroalkyl groups are preferred, perfluoromethyl groups, perfluoroethyl groups, perfluoropropyl groups, or more preferably perfluoroisopropyl groups, perfluorobutyl groups, or perfluoroisobutyl groups, and even more preferably perfluoromethyl groups. 28 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 28 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 Perfluoroalkyl groups are more preferred.
[0085] In general formula (E8), R 48 , R 49 , R 50 , R 51 , and R 52 These are, independently, a fluorine atom, a hydrogen atom, and C. 1-6 C11 is a perfluoroalkyl group, or a C11 is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 It is a perfluoroalkyl group. 48 , R 49 , R 50 , R 51 , and R 52 C 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 48 , R 49 , R 50 , R 51 , and R 52 Examples include linear or branched C 1-4 A perfluoroalkyl group is preferred, a perfluoromethyl group, a perfluoroethyl group, a perfluoropropyl group, or a perfluoroisopropyl group is more preferred, and a perfluoromethyl group is even more preferred. 48 , R 49 , R 50 , R 51, and R 52 C in which one or more ether-bonded oxygen atoms are introduced between carbon atoms. 1-6 If it is a perfluoroalkyl group, it may be a linear group or a branched group. 48 , R 49 , R 50 , R 51 , and R 52 This refers to linear or branched C atoms in which 1 to 3 ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is preferred, and a linear or branched C group is formed in which one or two ether-bonded oxygen atoms are introduced between carbon atoms. 1-4 A perfluoroalkyl group is more preferred, and a perfluoromethoxy group or a perfluoromethoxymethyl group is even more preferred.
[0086] In the general formula (E8), a8 is an integer of 1 or more, preferably an integer from 1 to 10, more preferably an integer from 1 to 6, and even more preferably an integer from 1 to 4. When a6 is an integer of 2 or more, there are multiple R 28 These may all be of the same kind, or they may be different from each other. In the general formula (E8), b8 is an integer of 1 or more, preferably an integer from 1 to 5, and more preferably an integer from 1 to 3. When b8 is an integer of 2 or more, there are multiple R 48 , R 49 , R 50 , R 51 , and R 52 These atoms may all be of the same type, or they may be different atoms. In general formula (E8), R Pf C 1-6 It is a perfluoroalkyl group. Pf For example, R in the general formula (E2) Pf Similar bases can be cited.
[0087] The groups represented by general formulas (E1) to (E8) all have 2 to 30 carbon atoms in the formula, and the ratio of oxygen atoms to fluorine atoms (O / F ratio) is 0.05 to 0.40, preferably 0.05 to 0.38, more preferably 0.05 to 0.37, and even more preferably 0.05 to 0.35. a1 to a8 and b1 to b8 are adjusted so that the number of carbon atoms and the O / F ratio are within the aforementioned ranges.
[0088] For example, the number of carbon atoms in the general formula (E1) is 1 + a1 × (1 + [R 21 [Number of carbon atoms inside]) + b1 × (2 + [R 31 [Number of carbon atoms inside] + [R] 32 The number of carbon atoms in the compound is a1 × (1 + [R 21 [Number of fluorine atoms inside]) + b1 × (2 + [R 31 [Number of fluorine atoms inside] + [R] 32 The number of fluorine atoms in the formula is a¹ × (R¹) + 1, and the number of oxygen atoms in the general formula (E1) is a¹ × (R¹) 21 (Number of oxygen atoms inside) + b1 × (1 + [R 31 [Number of oxygen atoms inside] + [R] 32 [Number of oxygen atoms inside]. Therefore, a1 and b1 in general formula (E1) are integers such that the following two equations hold true.
[0089] 2≦1+a1×(1+[R 21 [Number of carbon atoms inside]) + b1 × (2 + [R 31 [Number of carbon atoms inside] + [R] 32 [Number of carbon atoms inside]) ≤ 30 0.05 ≤ {a1 × (R 21 (Number of oxygen atoms inside) + b1 × (1 + [R 31 [Number of oxygen atoms inside] + [R] 32 [Number of oxygen atoms inside])} / {a1 × (1 + [R 21 [Number of fluorine atoms inside]) + b1 × (2 + [R 31 [Number of fluorine atoms inside] + [R] 32 [Number of fluorine atoms inside] + 1 ≤ 0.35
[0090] The fluorine-containing alkyl ether group used for modifying β-annular peptides is preferably a group represented by general formula (E1) or general formula (E2), and more preferably a group represented by general formula (E1). Among the fluorine-containing alkyl ether groups, in general formula (E1), a1 is an integer from 1 to 3, and R 21 Fluorine atom, trifluoromethyl group, perfluoropropyl group, perfluoroisopropyl group, perfluoroisobutyl group, trifluoromethoxy group, perfluoroethoxy group, -OCF 2 -O-CF 3 , or -OCF(-O-CF 3 ) 2 And R 31 and R 32 Each of these is independently a fluorine atom, a hydrogen atom, and a perfluoromethyl group, and it is preferable that b1 is an integer from 1 to 5; a1 is 1 or 2, R 21 Fluorine atom, trifluoromethyl group, perfluoropropyl group, perfluoroisopropyl group, perfluoroisobutyl group, trifluoromethoxy group, perfluoroethoxy group, -OCF 2 -O-CF 3 , or -OCF(-O-CF 3 ) 2 And R 31 and R 32 A group in which at least one of the atoms is a fluorine atom and the other is a fluorine atom, a hydrogen atom, or a perfluoromethyl group, and b1 is an integer from 1 to 3 is more preferred. In particular, as the fluorine-containing alkyl ether group, in general formula (E1), a1 is 1, and R 21 is a fluorine atom, R 31 and R 32 The group is a fluorine atom and b1 is 1; a1 is 1, R 21 is a fluorine atom, R 31 and R 32 The group is a fluorine atom and b1 is 2; a1 is 1, R 21 is a fluorine atom, R 31 and R 32 The group is a fluorine atom and b1 is 3; a1 is 2, R 21 is a fluorine atom, R 31 and R32 The group is a fluorine atom and b1 is 1; a1 is 2, R 21 is a fluorine atom, R 31 and R 32 The group is a fluorine atom, and b1 is 2; a2 is 2 and 1, R 21 is a fluorine atom, R 31 and R 32 The group is a fluorine atom and b1 is 3; a1 is 1, R 21 is a trifluoromethyl group, R 31 and R 32 The group is a fluorine atom and b1 is 1; a1 is 1, R 21 The group is a trifluoromethyl group, and b1 is 2; a1 is 1, R 21 is a trifluoromethyl group, R 31 and R 32 A group in which b1 is 3 is preferred, and b1 is fluorine.
[0091] <Long-chain group> At least a portion of the β-annular peptide constituting the artificial viral capsid according to the present invention may be a β-annular peptide modified with a long-chain group. The long-chain group used to modify the β-annular peptide is an alkyl group having 8 to 30 carbon atoms that is not substituted with a fluorine atom (long-chain alkyl group), or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of an alkyl group having 8 to 30 carbon atoms that is not substituted with a fluorine atom (long-chain alkyl ether group). The long-chain group in the long-chain modified β-annular peptide constituting the artificial viral capsid according to the present invention is C 8-25 Alkyl alkyl group or C 8-25 A group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of the alkyl group is preferred, C 8-25 More preferably, an alkyl group or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of the alkyl group, C 8-20 A group having an alkyl group or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of the alkyl group is even more preferred. Alkyl groups of sufficient length, like fluoroalkyl groups, are highly hydrophobic and contribute to cell membrane permeability.
[0092] <Fluorine-containing peptides and long-chain modified peptides> Among the β-annular peptides constituting the artificial viral capsid according to the present invention, the β-annular peptide modified with the fluorine-containing alkyl ether group is obtained by linking the β-annular peptide with a fluorine-containing peptide containing the fluorine-containing alkyl ether group. As the fluorine-containing peptide containing the fluorine-containing alkyl ether group, one to three of the fluorine-containing alkyl ether groups are linked directly or indirectly to the side chain of at least one amino acid residue among the amino acid residues constituting the peptide. The fluorine-containing peptide may be a peptide in which one fluorine-containing alkyl ether group is linked to the side chain of one to three amino acid residues, or it may be a peptide in which one fluorine-containing alkyl ether group is linked to the side chain of one amino acid residue. When multiple fluorine-containing alkyl ether groups are linked to one peptide, they may all be the same type of fluorine-containing alkyl ether group, or they may be different fluorine-containing alkyl ether groups.
[0093] Among the β-annular peptides constituting the artificial viral capsid according to the present invention, the β-annular peptide modified with the long-chain group is obtained by linking the β-annular peptide with a long-chain modified peptide containing the long-chain group. The long-chain modified peptide used is one in which 1 to 3 of the long-chain groups are directly or indirectly linked to the side chain of at least one amino acid residue among the amino acid residues constituting the peptide. The long-chain modified peptide may be a peptide in which one of the long-chain groups is linked to the side chains of 1 to 3 amino acid residues, or it may be a peptide in which 1 to 3 of the long-chain groups are linked to the side chain of one amino acid residue. When multiple long-chain groups are linked to one peptide, they may all be the same type of long-chain group, or they may be different long-chain groups from one another.
[0094] The amino acid residues constituting the fluorine-containing peptide and the long-chain modified peptide containing the fluorine-containing alkyl ether group are not particularly limited and may be α-amino acid residues, β-amino acid residues, γ-amino acid residues, or δ-amino acid residues. They may also be L-amino acid residues or D-amino acid residues. The amino acid residues that introduce the fluorine-containing alkyl ether group and the long-chain group into the side chain may be any of these amino acid residues.
[0095] The fluorine-containing peptide containing the fluorine-containing alkyl ether group and the long-chain group containing or long-chain modified peptide may be peptides consisting only of natural amino acid residues, peptides containing one or more artificial amino acid residues, or peptides consisting only of artificial amino acid residues. The amino acid residues into which the fluorine-containing alkyl ether group and the long-chain group are introduced into the side chains may be natural amino acid residues or artificial amino acid residues.
[0096] The fluorine-containing peptide containing the fluorine-containing alkyl ether group and the long-chain group containing or long-chain modified peptide are preferably peptides or modified versions thereof composed of amino acids that constitute proteins. Examples of amino acids that constitute proteins include glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, tryptophan, asparagine, glutamine, proline, aspartic acid, glutamic acid, lysine, arginine, histidine, and the like. Furthermore, examples of modified amino acids in which the amino acids constituting proteins have been modified include: amino acids in which the hydrogen atoms of the amino group in the side chain of lysine, arginine, and histidine are replaced with the amino group protecting groups mentioned above or the Pbf(N-ω-(2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl) group; amino acids in which the hydrogen atoms of the carboxyl group in the side chain of aspartic acid and glutamic acid are replaced with the carboxyl group protecting groups mentioned above or the alkyl group of the tert-butyl group; and amino acids in which the hydrogen atoms of the thiol group of cysteine are replaced with a benzyl group.
[0097] In fluorine-containing peptides, hydrogen atoms in the side chain of an amino acid residue may be directly substituted for the fluorine-containing alkyl ether group, or substituted via a linking group. In long-chain modified peptides, hydrogen atoms in the side chain of an amino acid residue may be directly substituted for the long-chain group, or substituted via a linking group. The linking group can be any group other than a methylene group in the portion that links to the fluorine-containing alkyl ether group or the long-chain group, and can be appropriately selected from divalent to tetravalent groups. For example, by using a tetravalent group, three fluorine-containing alkyl ether groups can be linked to one hydrogen atom in the side chain of an amino acid residue. Examples of linking groups that connect the fluorine-containing alkyl ether group or the long-chain group to atoms in the side chain of an amino acid residue include alkylene groups, oxygen atoms (-O-), sulfur atoms (-S-), -NH-, and -N(CH4). 3 )-,-N(C 2 H 5 )-,-N(C 3 H 7 )-, trivalent nitrogen atom, -C(=O)-, -S(=O)2 - Examples include groups obtained by removing 2 to 4 hydrogen atoms from cycloalkanes, groups obtained by removing 2 to 4 hydrogen atoms from aromatic rings (aryl groups), groups obtained by removing 2 to 4 hydrogen atoms from heterocycles (heteroaryl groups), or combinations thereof. Examples of groups obtained by removing 2 to 4 hydrogen atoms from cycloalkanes, aromatic rings, or heterocycles include groups obtained by removing 2 to 4 hydrogen atoms from cyclohexane, benzene, imidazole, or indole. For example, examples of groups obtained by removing 2 to 4 hydrogen atoms from benzene include 1,4-phenylene groups, 1,3-phenylene groups, 1,5-phenylene groups, or 1,3,5-substituted phenyl groups.
[0098] The fluorine-containing peptides or long-chain modified peptides possessed by the artificial viral capsid according to the present invention are, specifically, amino acid residues in which one or two hydrogen atoms of the amino group of the side chain of an arginine residue, asparagine residue, glutamine residue, or lysine residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group; amino acid residues in which a hydrogen atom of the imino group of the side chain of an arginine residue is substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group; amino acid residues in which a hydrogen atom of the carboxyl group of the side chain of an aspartic acid residue or glutamic acid residue is substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group; and hydrogen atoms of the thiol group of the side chain of a cysteine residue or methionine residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group. Peptides having at least one of the following are preferred: an amino acid residue substituted with a chain group; an amino acid residue in which a hydrogen atom of the hydroxyl group of the side chain of a serine residue, threonine residue, or tryptophan residue is substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group; an amino acid residue in which one to three hydrogen atoms of the benzene ring of the side chain of a tyrosine residue or phenylalanine residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group; an amino acid residue in which one to three hydrogen atoms of the imidazole ring of the side chain of a histidine residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group; or an amino acid residue in which one to three hydrogen atoms of the indole ring of the side chain of a tryptophan residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or the long-chain group.
[0099] Substitution of hydrogen atoms in the side chains of natural amino acids, such as amino groups, imino groups, carboxyl groups, hydroxyl groups, thiol groups, benzene rings, imidazole rings, and indole rings, with fluorine-containing alkyl ether groups or long-chain groups, either directly or via linking groups, can be carried out by general synthetic reactions such as esterification reactions.
[0100] The fluorine-containing peptide and long-chain modified peptide contained in the artificial viral capsid according to the present invention may be peptides consisting of two or more amino acids, and peptides consisting of three or more amino acids are also preferred. The amino acid residues constituting the fluorine-containing peptide or long-chain modified peptide contained in the artificial viral capsid according to the present invention are preferably 2 to 20, more preferably 3 to 20, even more preferably 3 to 10, and even more preferably 3 to 6.
[0101] In the fluorine-containing peptide of the artificial viral capsid according to the present invention, the amino acid residue having a fluorine-containing alkyl ether group in its side chain may be at the N-terminus, the C-terminus, or at a location other than the terminal. In the long-chain modified peptide of the artificial viral capsid according to the present invention, the amino acid residue having a long-chain group in its side chain may be at the N-terminus, the C-terminus, or at a location other than the terminal.
[0102] The fluorine-containing peptide or long-chain modified peptide of the artificial viral capsid according to the present invention is preferably a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, wherein the terminal connecting to the divalent linking group is a cysteine residue, and the second residue from the terminal opposite to the terminal connecting to the divalent linking group is a fluorine-containing amino acid residue or a long-chain group. The fluorine-containing peptide or long-chain modified peptide of the artificial viral capsid according to the present invention is preferably a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, wherein the N-terminus is a cysteine residue, and the second residue from the C-terminus is an amino acid residue in which a hydrogen atom of the side chain of a natural amino acid is replaced directly or via a linking group with the fluorine-containing alkyl ether group or a long-chain group; and the second to third residues from the N-terminus are A peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, where each amino acid residue is independently an alanine residue or a glycine residue; and a peptide consisting of 3 to 20, preferably 3 to 10, more preferably 3 to 6 amino acid residues, where the N-terminus is a cysteine residue, the second from the C-terminus is an amino acid residue in which a hydrogen atom of the side chain of a natural amino acid is replaced directly or via a linking group with the fluorine-containing alkyl ether group or long-chain group, the second from the N-terminus to the third from the C-terminus are independently alanine residues or glycine residues, and the C-terminus is a phenylalanine residue.Amino acid residues in which a hydrogen atom of the side chain of a natural amino acid is substituted with the fluorine-containing alkyl ether group or long-chain group, either directly or via a linking group, include: amino acid residues in which one or two hydrogen atoms of the amino group of the side chain of an arginine residue, asparagine residue, glutamine residue, or lysine residue are substituted with the fluorine-containing alkyl ether group or long-chain group, either directly or via a linking group; amino acid residues in which a hydrogen atom of the imino group of the side chain of an arginine residue is substituted with the fluorine-containing alkyl ether group or long-chain group, either directly or via a linking group; amino acid residues in which a hydrogen atom of the carboxyl group of the side chain of an aspartic acid residue or glutamic acid residue is substituted with the fluorine-containing alkyl ether group or long-chain group, either directly or via a linking group; and amino acid residues in which a hydrogen atom of the thiol group of the side chain of a cysteine residue or methionine residue is substituted with the fluorine-containing alkyl ether group or long-chain group, either directly or via a linking group. Preferably, the amino acid residue is one of the following: an amino acid residue substituted with a hydroxyl ether group or a long-chain group; an amino acid residue in which a hydrogen atom of the hydroxyl group of the side chain of a serine residue, threonine residue, or tryptophan residue is substituted directly or via a linking group with the fluorine-containing alkyl ether group or a long-chain group; an amino acid residue in which one to three hydrogen atoms of the benzene ring of the side chain of a tyrosine residue or phenylalanine residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or a long-chain group; an amino acid residue in which one to three hydrogen atoms of the imidazole ring of the side chain of a histidine residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or a long-chain group; or an amino acid residue in which one to three hydrogen atoms of the indole ring of the side chain of a tryptophan residue are substituted directly or via a linking group with the fluorine-containing alkyl ether group or a long-chain group.
[0103] The fluorine-containing peptides in the artificial viral capsid according to the present invention can be synthesized by general peptide synthesis methods, except that amino acids with a fluorine-containing alkyl ether group introduced in at least one side chain are used as raw material amino acids. For example, they can be synthesized by solid-phase peptide synthesis. These fluorine-containing peptides can be easily synthesized using an automated peptide synthesizer with amino acids having a fluorine-containing alkyl ether group introduced in one side chain as raw material. The long-chain modified peptides in the artificial viral capsid according to the present invention can be synthesized by general peptide synthesis methods, except that amino acids with a long-chain group introduced in at least one side chain are used as raw material amino acids. For example, they can be synthesized by solid-phase peptide synthesis. These long-chain modified peptides can be easily synthesized using an automated peptide synthesizer with amino acids having a long-chain group introduced in one side chain as raw material.
[0104] Peptides can be produced by sequentially condensing amino acids with protected amino groups with amino acids whose C-terminus is bonded to a solid phase, and then removing the peptide from the solid phase. It is preferable to use amino acid raw materials in which the amino group is protected with a Boc group or an Fmoc group. It is also preferable to use amino acid raw materials in which the side chain functional group is protected with a protecting group. Examples of protecting groups for side chain functional groups include the Boc group, triphenylmethyl group, benzyl group, and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) group.
[0105] Examples of condensing agents that form peptide bonds include N,N-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (WSC), benzotriazole-1-yloxytrisdimethylaminophosphonium hexafluorophosphate (BOP), benzotriazole-1-yloxytrispirolidinophosphonium hexafluorophosphate (pyBOP), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate, and 1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate (COMU). Furthermore, N-hydroxybenzotriazole (HOBt), (hydroxyimino)cyanoethyl acetate (oxyma), and the above-mentioned condensing agent can also be mixed in a preferred ratio and used.
[0106] Methods for activating the carboxyl terminus may be used to form peptide bonds, and examples of activators include N-hydroxysuccinimide, p-nitrophenyl esters, and pentafluorophenyl esters. Examples of bases used when forming peptide bonds include triethylamine and diisopropylethylamine (DIPEA). Examples of solvents used in the peptide bond formation reaction include chloroform, dichloromethane (DCM), dichloroethane (DCE), acetonitrile (MeCN), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and N-methyl-2-pyrrolidone (NMP).
[0107] The Boc and Fmoc groups, which are protecting groups for the amino-terminal amino groups of peptides or amino acids, can be removed by trifluoroacetic acid (TFA) or piperidine, respectively. Protecting groups for the side-chain functional groups of amino acid residues of peptides can be removed by, for example, TFA, hydrogen fluoride (HF), or trifluoromethanesulfonic acid.
[0108] Furthermore, in peptide solid-phase synthesis, TFA can be used, for example, to remove peptides with protecting groups attached to the side-chain functional groups of peptides or amino acid residues from the peptide solid-phase synthesis resin. The removal of peptides from the peptide solid-phase resin and the removal of protecting groups from the side-chain functional groups of amino acid residues can be carried out simultaneously within the same reaction system, or they can be carried out independently. As peptide solid-phase synthesis resins for peptide solid-phase synthesis, commercially available resins such as 4-hydroxymethyl-3-methoxyphenoxybutyrate-benzhydrylamine-polystyrene resin, p-benzyloxybenzyl alcohol-polystyrene resin, and oxime resins can be used.
[0109] The target peptide or its intermediate can be isolated and purified by various methods, such as ion chromatography, gel filtration chromatography, reverse-phase chromatography, normal-phase chromatography, recrystallization, extraction, and fractional crystallization. Furthermore, the peptides thus obtained can be converted to their respective salts by conventional methods.
[0110] The protecting groups of the amino or carboxyl groups of the manufactured fluorine-containing peptides or long-chain modified peptides can be deprotected as needed. Deprotection can be carried out by conventional methods depending on the type of protecting group.
[0111] In the artificial viral capsid according to the present invention, when the divalent linking group is linked to the N-terminus of a fluorine-containing peptide or a long-chain modified peptide, the C-terminus of the fluorine-containing peptide or the long-chain modified peptide may be protected with a protecting group. The protecting group for the C-terminus is not particularly limited as long as it is a carboxyl group protecting group, and for example, a carboxyl group protecting group used in peptide synthesis can be used. Specifically, the carboxyl group protecting group is a protecting group selected from the group represented by the following general formula (p-1), the 2-(9,10-dioxo)antrylmethyl group, the benzyloxymethyl group, and the phenacyl group. In the general formula (p-1), R 3 C may be substituted. 6-14 It is an aryl group, R 4 and R 5Each of these is independently a hydrogen atom or a substituted C 6-14 This is an aryl group. The black circles represent bonding bonds.
[0112]
[0113] Examples of protecting groups for carboxyl groups include benzyl group, diphenylmethyl group, triphenylmethyl group, 4-nitrobenzyl group, 4-methoxybenzyl group, 2,4-dimethoxybenzyl group, 3,4-dimethoxybenzyl group, 4-methylbenzyl group, 2,6-dimethylbenzyl group, 3-chlorobenzyl group, 9-anthrylmethyl group, piperonyl group, 2-(9,10-dioxo)anthrylmethyl group, benzyloxymethyl group, and phenacyl group. In terms of being able to deprotect under mild conditions, the protecting group for the C-terminal carboxyl group is preferably benzyl group or triphenylmethyl group, and more preferably benzyl group.
[0114] In the artificial viral capsid according to the present invention, if the divalent linking group is linked to the N-terminus of a fluorine-containing peptide or a long-chain modified peptide, the N-terminus of the fluorine-containing peptide or the long-chain modified peptide may be protected with an amino group protecting group. The N-terminal protecting group is not particularly limited as long as it is an amino group protecting group, and for example, amino group protecting groups used in peptide synthesis can be used. Examples of amino group protecting groups include carbamate protecting groups such as tert-butoxycarbonyl (Boc) group, 9-fluorenylmethyloxycarbonyl (Fmoc) group, benzyloxycarbonyl (Cbz) group, allyloxycarbonyl (Alloc) group, and 2,2,2-trichloroethoxycarbonyl (Troc) group. Preferably, the tert-butoxycarbonyl (Boc) group or the 9-fluorenylmethyloxycarbonyl (Fmoc) group can be deprotected under mild conditions.
[0115] The fluorine-modified β-annular peptide of the artificial viral capsid according to the present invention may be bound to another substance at the end of the β-annular peptide that is not bound to the divalent linking group. The long-chain modified β-annular peptide of the artificial viral capsid according to the present invention may be bound to another substance at the end of the β-annular peptide that is not bound to the divalent linking group. The other substance is not particularly limited as long as it does not inhibit the formation of the artificial viral capsid by the self-assembly of the β-annular peptide, and the same substances as those listed as other substances that may be bound to the end of the cancer-specific ligand-modified β-annular peptide that is not bound to the divalent linking group can be used.
[0116] <Artificial Viral Capsid> The subunits constituting the artificial viral capsid according to the present invention may consist only of cancer-specific ligand-modified β-annular peptides, or may consist of cancer-specific ligand-modified β-annular peptides and unmodified β-annular peptides, or may consist of cancer-specific ligand-modified β-annular peptides and fluorine-modified β-annular peptides, or may consist of cancer-specific ligand-modified β-annular peptides and long-chain modified β-annular peptides, or may consist of cancer-specific ligand-modified β-annular peptides, fluorine-modified β-annular peptides and unmodified β-annular peptides, or may consist of cancer-specific ligand-modified β-annular peptides, long-chain modified β-annular peptides and unmodified β-annular peptides, or may consist of cancer-specific ligand-modified β-annular peptides, unmodified β-annular peptides and other modified β-annular peptides. Other modified β-annular peptides are not particularly limited, as long as they are modified β-annular peptides that do not contain cancer-specific ligands, fluorine-containing peptides, or long-chain modified peptides, and in which substances other than cancer-specific ligands, fluorine-containing groups, and long-chain modified peptides are linked to the N-terminus and / or C-terminus of the β-annular peptide. Substances other than cancer-specific ligands, fluorine-containing peptides, and long-chain modified peptides are not particularly limited, as long as they do not inhibit the formation of artificial viral capsids by the self-assembly of β-annular peptides, and include peptides, nucleic acids, small molecule compounds, and chimeric molecules consisting of two or more of these.
[0117] In order to obtain an artificial viral capsid that is more useful as a cancer cell-specific DDS carrier, the ratio of the number of molecules of cancer-specific ligand-modified β-annular peptide to the total number of molecules of subunits (β-annular peptides) constituting the artificial viral capsid according to the present invention is preferably 5 mol% or more, more preferably 5 to 100 mol%, even more preferably 10 to 90 mol%, even more preferably 15 to 80 mol%, even more preferably 15 to 60 mol%, and particularly preferably 15 to 40 mol%. If the artificial viral capsid according to the present invention has a fluorine-modified β-annular peptide, the ratio of the number of molecules of cancer-specific ligand-modified β-annular peptide to the total number of molecules of subunits (β-annular peptides) constituting the artificial viral capsid according to the present invention is preferably 5 mol% or more, more preferably 5 to 30 mol%, even more preferably 5 to 25 mol%, even more preferably 10 to 25 mol%, and particularly preferably 15 to 25 mol%.
[0118] When the artificial viral capsid according to the present invention has a fluorine-modified β-annular peptide, it exhibits superior cell membrane permeability, resulting in an artificial viral capsid that is more useful as a cancer cell-specific DDS carrier. Therefore, the ratio of the number of molecules of the fluorine-modified β-annular peptide to the total number of molecules of the subunits (β-annular peptides) constituting the artificial viral capsid according to the present invention is preferably 40 mol% or more, more preferably 45 to 95 mol%, even more preferably 50 to 85 mol%, even more preferably 60 to 80 mol%, and particularly preferably 60 to 70 mol%. When the artificial viral capsid according to the present invention has a long-chain modified β-annular peptide, it exhibits superior cell membrane permeability, resulting in an artificial viral capsid that is more useful as a cancer cell-specific DDS carrier. Therefore, the ratio of the number of molecules of the long-chain modified β-annular peptide to the total number of molecules of the subunits (β-annular peptides) constituting the artificial viral capsid according to the present invention is preferably 40 mol% or more, more preferably 45 to 95 mol%, even more preferably 50 to 85 mol%, even more preferably 60 to 80 mol%, and particularly preferably 60 to 70 mol%.
[0119] The artificial viral capsid according to the present invention is formed by the self-assembly of a raw material β-annular peptide. Here, "raw material β-annular peptide" refers to a β-annular peptide that becomes a component of the artificial viral capsid through self-assembly, and includes not only unmodified β-annular peptides but also modified β-annular peptides capable of self-assembly. The composition of the subunits constituting the artificial viral capsid according to the present invention is approximately equal to the composition of the raw material β-annular peptide. Therefore, by adjusting the composition of the raw material β-annular peptide, an artificial viral capsid with a desired subunit composition can be obtained.
[0120] The artificial viral capsid according to the present invention may use only fluorine-modified β-annular peptide as the raw material β-annular peptide, or it may use fluorine-modified β-annular peptide and unmodified β-annular peptide, or it may use fluorine-modified β-annular peptide and other modified β-annular peptide, or it may use fluorine-modified β-annular peptide, other modified β-annular peptide and unmodified β-annular peptide as the raw material β-annular peptide. The artificial viral capsid according to the present invention may use only long-chain modified β-annular peptide as the raw material β-annular peptide, or it may use long-chain modified β-annular peptide and unmodified β-annular peptide, or it may use long-chain modified β-annular peptide and other modified β-annular peptide and unmodified β-annular peptide as the raw material β-annular peptide.
[0121] The content ratio (molar ratio) of cancer-specific ligand-modified β-annular peptide to the total amount of raw material β-annular peptide is 5 mol% or more, preferably 5 to 100 mol%, more preferably 10 to 80 mol%. In particular, when the cancer-specific ligand is folic acid, the ratio is further preferably 15 to 60 mol%, even more preferably 15 to 40 mol%, and especially preferably 15 to 30 mol%, thereby obtaining an artificial viral capsid in which the ratio of the number of molecules of cancer-specific ligand-modified β-annular peptide to the total number of molecules of β-annular peptide constituting the artificial viral capsid is 5 mol% or more, preferably 5 to 100 mol%, more preferably 10 to 80 mol%, even more preferably 15 to 60 mol%, even more preferably 15 to 40 mol%, and especially preferably 15 to 30 mol%.
[0122] In particular, since a useful artificial viral capsid with enhanced targeting of cancer cells possessing folate receptors can be obtained, the artificial viral capsid according to the present invention is preferably an artificial viral capsid containing both a cancer-specific ligand-modified β-annular peptide (folate-modified β-annular peptide) and a fluorine-modified β-annular peptide, or an artificial viral capsid containing both a folate-modified β-annular peptide and a long-chain modified β-annular peptide. In the case of an artificial viral capsid containing both a folate-modified β-annular peptide and a fluorine-modified β-annular peptide or a long-chain modified β-annular peptide, the content ratio (molar ratio) of the folate-modified β-annular peptide to the total amount of β-annular peptide constituting the artificial viral capsid is preferably 5 mol% or more, more preferably 5 to 30 mol%, even more preferably 5 to 25 mol%, even more preferably 10 to 25 mol%, and particularly preferably 15 to 25 mol%.
[0123] The artificial viral capsid according to the present invention is produced by self-assembling a β-annular peptide, which is a raw material containing a cancer-specific ligand-modified β-annular peptide, in a solvent. The solvent used for self-assembly is not particularly limited as long as it is a solvent in which the β-annular peptide can be dissolved, and may be water, a buffer, or a mixed solvent of water or a buffer and one or more organic solvents. Examples of organic solvents include DMS, DMF, acetonitrile, acetone, tetrahydrofuran (THF), glycerin, ethylene glycol, propylene glycol, and ethanol.
[0124] If the solvent used for self-assembly is an aqueous solvent that does not contain organic solvents, the pH of the solvent is typically 5.0 to 9.0, and may be, for example, 6.0 to 8.0 or 6.5 to 7.5. The concentration of the subunits during self-assembly (the concentration of the β-annular peptide raw material) may be, for example, 1.0 to 50 μM, 1.0 to 30 μM, or 1.0 to 20 μM.
[0125] The artificial viral capsid according to the present invention exhibits excellent cancer cell specificity because it is modified with a cancer-specific ligand. Therefore, this artificial viral capsid is expected to be used in the pharmaceutical field as a physiologically active substance. For example, the artificial viral capsid according to the present invention is useful as a DDS carrier for transporting target substances into cancer cells. For example, in the artificial viral capsid according to the present invention, the target substance to be transported into the cell is linked to the N-terminus of the β-annular peptide, and the artificial viral capsid is formed by self-assembly. The artificial viral capsid obtained thereby encapsulates the target substance and its surface is modified with a cancer-specific ligand, allowing the target substance to be efficiently taken up by cancer cells.
[0126] If the artificial viral capsid according to the present invention also includes a fluorine-modified β-annular peptide or a long-chain modified β-annular peptide, the artificial viral capsid has excellent cell membrane permeability because it has a fluorine-containing group or a long-chain group on its surface. For example, in the artificial viral capsid according to the present invention, the target substance to be transported into the cell is linked to the N-terminus of the β-annular peptide, and the artificial viral capsid is formed by self-assembly. The artificial viral capsid obtained thereby encapsulates the target substance, and its surface is modified with a cancer-specific ligand and a fluorine-containing group or a long-chain group, so the target substance can be taken up into target cancer cells very efficiently.
[0127] Furthermore, in transfection, the cytotoxicity of the transfection reagent used also affects the efficiency of cell delivery of the target substance. With highly cytotoxic reagents, the survival rate of cells after delivery is significantly reduced, resulting in lower delivery efficiency. In contrast, the artificial viral capsid according to the present invention has relatively low cytotoxicity. Therefore, it is possible to efficiently deliver the target substance to various cell types without excessively reducing cell survival rates.
[0128] The artificial viral capsid according to the present invention can also encapsulate a target substance to be delivered into the cells of a target cancer as a guest substance. For example, when the subunits of the artificial viral capsid according to the present invention are self-assembled in an aqueous medium, the target substance can be dissolved or dispersed in the aqueous medium to obtain an artificial viral capsid encapsulating the target substance. The aqueous medium may be water, a buffer such as phosphate saline (PBS), or a solution containing a small amount of organic solvent.
[0129] The target substance to be delivered into cells and encapsulated in the artificial viral capsid according to the present invention is not particularly limited as long as it is a substance that can be encapsulated in the artificial viral capsid formed by the β-annular peptide. Examples include substances used for cell labeling such as fluorescent substances and quantum dots, and physiologically active substances such as pharmacoactive ingredients. The pharmacoactive ingredient to be encapsulated in the artificial viral capsid according to the present invention may be any of the following: peptides, nucleic acids, small molecule compounds, and chimeric molecules consisting of two or more of these. Examples of nucleic acids include nucleic acids that contribute to RNA interference, such as siRNA, and nucleic acids for genetic recombination and genome editing (e.g., mRNA). In other words, the artificial viral capsid according to the present invention can be used as an active ingredient in a DDS carrier composition by encapsulating the target substance. Because the artificial viral capsid according to the present invention contains a β-annular peptide modified with a fluorine-containing alkyl ether group as a component, it has a higher intracellular delivery capacity than artificial viral capsids modified with fluorine-containing alkyl groups, allowing the encapsulated target substance to be introduced into target cells and exert its desired effect more fully.
[0130] The DDS carrier composition may contain, in addition to the artificial viral capsid, pharmaceutically acceptable carriers, excipients, additives, etc., as appropriate. An example of a suitable carrier is water, but it may also be an aqueous solution containing a salt (electrolyte) at a concentration suitable for administration to the human body, or a mixed solvent containing an organic solvent such as alcohol in water. Routes of administration include, but are not limited to, oral, intravenous, intra-arterial, intramuscular, subcutaneous, transdermal, intraperitoneal, intrathecal, transrectal, transvaginal, ocular, and inhalation.
[0131] The artificial viral capsid according to the present invention can be used to treat diseases in which a therapeutic effect can be obtained by encapsulating a pharmacoactive ingredient. In other words, the artificial viral capsid according to the present invention can be used as an active ingredient in a pharmaceutical composition. A pharmaceutical composition can be prepared by encapsulating a therapeutically effective amount of a pharmacoactive ingredient inside the artificial viral capsid in a DDS carrier composition. As the pharmacoactive ingredient, an ingredient that targets cancer cells, such as an anticancer drug, is preferred. The target of administration of the artificial viral capsid according to the present invention or a composition containing the same is typically an animal, such as a mammal, particularly a human, but the target of administration may also be the in vitro tissue or cultured cells of these animals.
[0132] The present invention will be described below with reference to examples, but the present invention is not limited to these examples.
[0133] <MALDI-TOF-MS> (Method) A 1 μL solution of α-CHCA saturated acetone was added dropwise to a mass plate (MTP 384 target plate ground steel TF), and the solvent was removed after incubation for a while. Next, a 1 μL sample solution was added dropwise to the plate, followed by the addition of another α-CHCA saturated solution, and the solution was removed under vacuum. The sample was measured using "ultrafleXtreme (Bruker Daltonics)".
[0134] (Purification conditions) Column: Inertsil WP300 C18 (5 μm, 20 × 250 mm) Gradient solvent: (A) Acetonitrile containing 0.1% TFA (trifluoroacetic acid), (B) Deionized water containing 0.1% TFA Gradient conditions: (A) 5% (0 min) → 100% (95 min), (B) 95% (0 min) → 0% (95 min) Flow rate: 10 mL / min Sample injection volume: 500 μL Detection: UV-vis 220 nm
[0135] <Measurement of Particle Size by Dynamic Light Scattering (DLS)> The particle size of the artificial virus capsid in each sample was measured by dynamic light scattering. The measurement was performed at 25°C using a DLS dynamic light scattering instrument (Zetasizer Nano ZS, MALVERN) equipped with an incident He-Ne laser (633 nm) and a low-volume glass cuvette cell (12 μL, ZEN2112, Malvern). 10 mM phosphate buffer (pH 7.4) was used as the solvent. During the measurement, the sample diffusion intensity was displayed, and the correlation time of the scattering intensity G(τ) was measured 10 times and the averaged value was applied to the following formula (1).
[0136] [B: baseline, A: amplitude, q: scattering vector, τ: delay time, D: diffusion coefficient:]
[0137] Hydrodynamic radius of scattered particles (R H The value was calculated using the Stokes-Einstein equation, which is shown in equation (2) below.
[0138] [η: solvent viscosity, k B : Boltzmann's constant, T: absolute temperature.]
[0139] <Observation by Transmission Electron Microscope (TEM)> Artificial virus capsids in each sample were observed using a TEM (JEM 1400 Plus, JEOL). The TEM grid (Thin Carbon film TEM grids, ALLANCE Biosystems) was hydrophilized by plasma treatment (25°C, 60Hz, 500VA, 40s, JEOL HD Treatment). A sample aqueous solution (5 μL) was added to the hydrophilized TEM grid, incubated for 1 minute, and then removed. Subsequently, a staining agent (5 μL, EM Stainer, Nisshin EM) was added to the TEM grid, allowed to stand for 1 minute, and then removed. After staining, the grid was dried under reduced pressure and observed using a TEM at an accelerating voltage of 80 kV.
[0140] <Cell Culture> Human cervical cancer-derived HeLa cells and human liver cancer-derived HepG2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma). All culture media contained 10 v / v% fetal bovine serum (FBS), 100 μg / mL streptomycin, 100 units / mL penicillin, 1 mM sodium pyruvate, and 1 v / v% MEM nonessential amino acids. The cells were then exposed to 5% CO2. 2 The culture was maintained at 37°C in an incubator, and subculture was performed every 3-4 days.
[0141] [Reference Example 1] An artificial viral capsid was formed by self-assembling subunits, each consisting of a β-annular peptide and a fluorine-containing peptide linked by a Bis-maleimide group.
[0142] (1) Synthesis of β-annulars-PEG2-maleimide
[0143]
[0144] 1,2-Bis(2-maleimideethoxy)ethane [bismaleimide-PEG2] (1 mg) was weighed out and dissolved in acetonitrile (500 μL). Next, β-Annulus-Cys (INHVGGTGGAIMAPVAVTRQLVCS: SEQ ID NO: 2) (1 mg) was weighed out and dissolved in deionized water (500 μL), and added to the bismaleimide-PEG2-acetonitrile solution. The resulting mixture was stirred at 37°C for 12 hours (final concentration: β-Annulus-Cys 425 μM, bismaleimide-(PEG) 2 (3.2 mM). The reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS.
[0145] In RP-HPLC, a peak of the purified product was observed around 38 minutes. Analysis of the purified product at this peak using MALDI-TOF-MS revealed a m / z value of 2659.6 [M+H] for β-annular-PEG2-maleimide. + (The calculated value was 2660.3.)
[0146] (2) Synthesis of TMR (tetramethylrhodamine)-β-annulus-PEG2-maleimide
[0147]
[0148] 1,2-Bis(2-maleimideethoxy)ethane [bismaleimide-PEG2] (1.1 mg) was weighed out and dissolved in acetonitrile (500 μL). Next, TMR-β-Annulus-Cys (1 mg) was weighed out and dissolved in a mixture of acetonitrile (250 μL) and deionized water (500 μL), and this was added to the bismaleimide-PEG2-acetonitrile solution. The resulting mixture was stirred at 37°C for 12 hours (final concentrations: TMR-β-Annulus-Cys 286 μM, bismaleimide-(PEG)2 3.2 mM). The reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS.
[0149] In RP-HPLC, a peak of the purified product was observed around 40 minutes. Analysis of the purified product at this peak using MALDI-TOF-MS revealed that it was TMR-β-annular-PEG2-maleimide with a m / z value of 3072.0 [M+H]. + (The calculated value was 3071.5.)
[0150] (3) Synthesis of β-annulus-PFE
[0151]
[0152] Perfluoroalkyl ether group (-CH 2 -CF 2 -O-CF 2 -CF 2 -O-CF 2 -CF 3A fluorine-containing peptide (hereinafter sometimes referred to as "PFE") (1 mg), obtained by linking the carboxyl group of the side chain of the aspartic acid residue of the tetrapeptide (CANF: SEQ ID NO: 3) with a divalent group consisting of one hydrogen atom removed from the amino group and one hydrogen atom removed from the hydroxyl group of 4-aminophenol, was dissolved in DMF (50 μL) and added to a solution of β-Annulus-PEG2-maleimide (1 mg) in another DMF (50 μL). DIPEA (3-6 μL) was added to the resulting mixture and stirred at 25°C for 8-12 hours (final concentrations: β-Annulus-PEG2-maleimide 3.67 mM, PFE 11.6 mM). The reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS.
[0153] In RP-HPLC, a peak of the purified product was observed around 53 minutes. Analysis of the purified product at this peak using MALDI-TOF-MS revealed a β-annular-PFE m / z value of 3517.9 [M+H]. + (The calculated value was 3518.5.)
[0154] (4) TMR synthesis of TMR-β-annulus-PFE
[0155]
[0156] PFE (1 mg) was dissolved in DMF (50 μL) and added to a solution of TMR-β-annular-PEG2-maleimide (1.0 mg) in another DMF (50 μL). DIPEA (3–6 μL) was added to the resulting mixture and stirred at 25°C for 6 hours (final concentrations: β-annular-PEG2-maleimide 3.25 mM, PFE 11.6 mM). The reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS.
[0157] In RP-HPLC, a peak of the purified product was observed around 54 minutes. Analysis of the purified product at this peak using MALDI-TOF-MS revealed a TMR-β-annular-PFE with a m / z value of 3929.9 [M+H]. + (The calculated value was 3930.6.)
[0158] (5) Synthesis of TMR-PFE
[0159]
[0160] PFE (0.5 mg) was dissolved in DMSO (250 μL), and added to a solution of TMR-5-maleimide (0.5 mg) in another portion of DMSO (250 μL). The resulting mixture was stirred at 25°C for 8 to 12 hours in the dark (final concentrations: TMR-5-maleimide 2.08 μM, PFE 1.16 μM). The reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS.
[0161] In RP-HPLC, a peak of the purified product was observed around 58 minutes. When the purified product at this peak was analyzed by MALDI-TOF-MS, the m / z of TMR-β-annulus-PFE was 1340.5 [M+H] + (calculated value: 1339.4).
[0162] <Formation of β-annulus-PFE-modified artificial virus capsid> The PFE-modified virus capsid solution was prepared by mixing 50 μM β-annulus-PFE solution (20 μL), 50 μM β-annulus (30 μL), and PBS (pH 7.5, 50 μL), followed by stirring for 30 seconds to form capsids (final concentrations in PBS (pH 7.5): β-annulus-PFE 10 μM, β-annulus 15 μM). The particle size of the obtained β-annulus-PFE-modified artificial virus capsid was measured by DLS and found to be 140.5±14.5 nm.
[0163] <Formation of TMR-labeled β-annulus-PFE-modified artificial virus capsid> The TMR-labeled β-annulus-PFE-modified artificial virus capsid solution was prepared by mixing 50 μM β-annulus-PFE solution (20 μL), 50 μM β-annulus (20 μL), 50 μM TMR-β-annulus-PFE solution (10 μL), and PBS (pH 7.5, 50 μL), followed by stirring for 30 seconds to form capsids (final concentrations in PBS (pH 7.5): β-annulus-PFE 10 μM, β-annulus 10 μM, TMR-β-annulus-PFE 5 μM). The particle size of the obtained TMR-labeled β-annulus-PFE-modified artificial virus capsid was measured by DLS and found to be 150.0±40.5 nm.
[0164] <Intracellular Transport of β-annulus-PFE Modified Artificial Viral Capsid> HeLa cells were cultured in the following four types of solutions, and the intracellular uptake of each TMR-labeled molecule was examined. Solution A: A solution containing 20 μM β-annulus and 5 μM TMR-β-annulus in DMEM. Solution B: A solution containing 25 μM TMR-PFE in DMEM. Solution C: A solution containing 25 μM TMR-β-annulus-PFE in DMEM. Solution D: A solution containing 10 μM β-annulus, 10 μM β-annulus-PFE, and 5 μM TMR-β-annulus in DMEM.
[0165] First, 100 μL of HeLa cells were added to a single-well glass-bottom dish at 2.0×10 4 cells / well, followed by incubation at 37°C for 24 hours in a 5% CO 2 incubator. Next, the aforementioned Solutions A to D were added to the cells in the dish, and the mixture was incubated at 37°C for 24 hours in a 5% CO 2 incubator. After incubation, the culture medium was removed, the cells were washed with PBS, a Hoechst 33342 (manufactured by Thermo Fisher SCIENTIFIC) solution (10 μg / mL, 80 μL) was added, and the mixture was incubated at 25°C for 10 minutes. After incubation, the Hoechst 33342 solution was removed, the cells were washed with PBS, DMEM (containing 10% FBS) (100 μL) was added, and observation was performed with a confocal scanning microscope (CLSM, FLUOVIEW FV10i, manufactured by Olympus Corporation).
[0166] Figure 1 shows microscopic images of HeLa cells cultured in each solution. From the cells cultured in Solution A, which contains viral capsids formed by the self-assembly of β-annulus and TMR-β-annulus, fluorescence from TMR was detected but was weak. On the other hand, strong fluorescence from TMR was observed in all of the cells cultured in Solution B containing TMR-PFE, and the cells cultured in Solutions C and D containing PFE-modified TMR-labeled viral capsids.
[0167] Similarly, for HepG2 cells, add solutions A to D, and 5% CO2 2 After incubation at 37°C for 24 hours in an incubator, the samples were washed with PBS, stained with Hoechst 33342, and then observed with a confocal scanning microscope.
[0168] Figure 2 shows microscopic images of HepG2 cells cultured in each solution. Similar to HeLa cells, fluorescence from cells cultured in solution A was weak in HepG2 cells, but fluorescence from TMR was observed in cells cultured in solutions B and C. These results indicate that viral capsids containing PFE-modified β-annulares have significantly higher intracellular transport efficiency compared to viral capsids without PFE modification, and that this improvement in intracellular transport efficiency due to PFE modification is exerted in both HeLa cells and HepG2 cells.
[0169] The fluorescence intensity of TMR was normalized by subtracting the extracellular fluorescence intensity from the intracellular fluorescence intensity using the image analysis software "Image J". The average values of the TMR fluorescence intensity detected from each cell (n=60) are shown in Table 1.
[0170]
[0171] [Reference Example 2] Using the β-annulus, TMR-β-annulus, and β-annulus-PFE used in Reference Example 1, viral capsids with different subunit compositions were formed, and the effect of the subunit composition on the cell membrane permeability of the viral capsid was investigated.
[0172] Raw material solutions containing β-annulus, TMR-β-annulus, and β-annulus-PFE at the concentrations shown in Table 2 were prepared. These raw material solutions were freeze-dried, the solvent was removed, and then the viral capsids were formed by self-assembly in a solution dissolved in DMEM. The subunit ratio of the formed viral capsids was approximately equal to the composition ratio of the raw material solutions.
[0173]
[0174] The viral capsids formed in test plots 1-2 to 1-10 were added to the culture medium of HepG2 cells in the same manner as in Reference Example 1, and 5% CO2 was added. 2 After incubation at 37°C for 24 hours in an incubator, the cells were washed with PBS and stained with Hoechst 33342, followed by observation with a confocal scanning microscope. The TMR fluorescence intensity was normalized in the same manner as in Reference Example 1, and the average TMR fluorescence intensity detected from each cell was calculated. The results are shown in Table 3.
[0175]
[0176] As shown in Table 3, the higher the ratio of β-annular-PFE content to the total subunits constituting the viral capsid, the higher the TMR fluorescence intensity of cells that incorporated the viral capsid. These results suggest that the higher the ratio of fluorine-modified β-annular peptide content to the total subunits constituting the viral capsid, the better the cell membrane permeability. In particular, if the content ratio of fluorine-modified β-annular peptide is 40 mol% or higher, the intracellular transport efficiency is high, making it suitable as a DDS carrier. A content ratio of fluorine-modified β-annular peptide of 50 mol% or higher is especially effective.
[0177] Similarly, raw material solutions containing β-annulus, TMR-β-annulus, and β-annulus-PFE at the concentrations shown in Table 4 were prepared. These raw material solutions were freeze-dried, the solvent was removed, and then the virus capsids were formed by self-assembly in a solution dissolved in DMEM.
[0178]
[0179] The viral capsids formed in test plots 2-1 to 2-9 were added to the culture medium of HepG2 cells in the same manner as in Reference Example 1, and 5% CO2 was added. 2After incubation at 37°C for 24 hours in an incubator, the cells were washed with PBS, stained with Hoechst 33342, and then observed with a confocal scanning microscope. The TMR fluorescence intensity was normalized in the same manner as in Reference Example 1, and the average TMR fluorescence intensity detected from each cell was calculated. The results are shown in Table 4. In this test group as well, the TMR fluorescence intensity of cells that incorporated the viral capsid increased as the ratio of β-annular-PFE content to the total subunits constituting the viral capsid increased.
[0180] [Reference Example 3] To investigate the intracellular uptake pathway of viral capsids containing PFE-modified β-annular peptide, intracellular uptake of viral capsids was performed in the presence of an endocytosis inhibitor. Viral capsids containing PFE-modified β-annular peptide were formed using β-annular, TMR-β-annular, and β-annular-PFE as used in Reference Example 1.
[0181] As endocytosis inhibitors, we used EIPA (5-(N-ethyl-N-isopropyl)-amyloride) (Mw: 299.8, manufactured by Funakoshi Co., Ltd.), a macropinocytosis inhibitor; Pitstop2 (N-[5-(4-bromobenzylidene)-4-oxo-4,5-dihydro-1,3-thiazole-2-yl]naphthalene-1-sulfonamide) (Mw: 473.36, manufactured by Sigma-Aldrich Co., Ltd.), a clathrin-dependent endocytosis inhibitor; and Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) (Mw: 270.2, manufactured by Funakoshi Co., Ltd.), a caveolae-dependent endocytosis inhibitor.
[0182] Place 100 μL of HepG2 cells in a single-well glass-bottom dish, 2.0 × 10 4 Add enough cells per well, then add 5% CO2. 2The mixture was incubated in an incubator at 37°C for 24 hours. Then, 60 μL each of DMEM (containing 10% FBS) containing EIPA (final concentration 50 μM), Genistein (final concentration 200 μM), or Pitstop2 (final concentration 25 μM) was added to the wells of the dish, and 5% CO2 was added. 2 The cells were incubated in an incubator at 37°C for 30 minutes. Afterward, the supernatant was removed and the cells were washed with PBS(-).
[0183] Next, to the washed cells, a solution of TMR-labeled PFE-modified β-annular virus capsid (10 μM β-annular, 10 μM β-annular-PFE, 5 μM TMR-β-annular) or TMR-PFE peptide (25 μM) added to DMEM (containing 10% FBS) solution (100 μL) is added, followed by 5% CO2. 2 The cultures were incubated in an incubator at 37°C for 24 hours. As a control, 100 μL of DMEM (containing 10% FBS) without the inhibitor was added and incubated in the same manner. After incubation, the culture supernatant was removed, washed with PBS, and Hoechst 33342 solution (10 μg / mL, 80 μL) was added, followed by incubation at 25°C for 10 minutes. After incubation, the Hoechst 33342 solution was removed, washed with PBS, and DMEM (containing 10% FBS) (100 μL) was added. The cultures were then observed using a confocal scanning microscope (CLSM, FLUOVIEW FV10i, Olympus).
[0184] The TMR fluorescence intensity was normalized from the acquired microscope images in the same manner as in Reference Example 1, and then the average TMR fluorescence intensity detected from each cell was calculated. The results are shown in Table 5.
[0185]
[0186] As shown in Table 5, the addition of endocytosis inhibitors reduced the intracellular TMR fluorescence intensity, confirming that both the TMR-labeled PFE-modified β-annular virus capsid and the TMR-PFE peptide were inhibited from being taken up into cells. In particular, the TMR fluorescence intensity of the TMR-labeled PFE-modified β-annular virus capsid was significantly reduced in cells treated with Genistein and Pitstop2, suggesting that the TMR-labeled PFE-modified β-annular virus capsid is primarily taken up into cells via both caveola-dependent endocytosis and clathrin-dependent endocytosis. Since clathrin-dependent endocytosis and caveola-dependent endocytosis are major endocytosis pathways in many cells, and substances can be taken up into cells via these pathways, the artificial viral capsid according to the present invention is useful as a DDS carrier for transporting target substances to a wide variety of cells.
[0187] [Reference Example 4] Doxorubicin (Dox) was encapsulated in an artificial viral capsid formed by self-assembling β-annular peptide and PFE-modified β-annular peptide, and the PFE-modified β-annular peptide was transported into cells. The viral capsid containing the PFE-modified β-annular peptide was formed using the β-annular, TMR-β-annular, and β-annular-PFE used in Reference Example 1.
[0188] (Formation of Dox-encapsulated viral capsids) A 10 mM Dox / DMSO solution (1 μL) and a 10 mM β-annular-PFE-viral capsid / DMSO solution (6 mM β-annular, 4 mM β-annular-PFE) (1 μL) were mixed, and then PBS (98 μL) was added and the mixture was stirred for 30 seconds (final concentration: 100 μM Dox, 100 μM β-annular-PFE). Then, free Dox and DMSO were removed by 12 hours of dialysis (dialysis tube, 1 kDa cutoff).
[0189] The concentration of Dox encapsulated in the viral capsid (Dox binding rate (%): [Total amount of added drug] - [Amount of unencapsulated free drug] / [Total amount of added drug] × 100%) was calculated by UV-vis spectral measurement using the Nanodrop ultra-trace spectrophotometer (Thermo Scientific) with the post-dialysis solution (molar extinction coefficient of Dox ε480 = 11500M). -1 cm -1 ) (Non-patent document 5). Specifically,
[0190] (DLS measurement conditions) Cell: ZEN2112 - low volume glass cuvette (12 μL) Temperature: 25°C
[0191] (Electron microscope measurement conditions) Acceleration voltage: 80 kV
[0192] The number-average particle size of the formed Dox-encapsulated viral capsid was 128 ± 44.5 nm. A TEM image of the Dox-encapsulated viral capsid is shown in Figure 3. As shown in Figure 3, it was demonstrated that even when Dox was encapsulated, the viral capsid containing the PFE-modified β-annular peptide stably self-assembled to form a capsid. The Dox binding rate of the Dox-encapsulated viral capsid was 24%.
[0193] (Introduction of Dox-encapsulated viral capsid into cells) 100 μL of HepG2 cells are placed in a single-well glass-bottom dish in a 2.0 × 10⁶ container. 4 Add enough cells per well, then add 5% CO2. 2 The mixture was incubated in an incubator at 37°C for 24 hours. Next, after removing the supernatant from the wells of the dish, a solution of Dox (final concentration 960 nM) or Dox-encapsulated viral capsid (2.4 μM β-annulus, 1.6 μM β-annulus-PFE, 960 nM Dox) added to a DMEM (containing 10% FBS) solution (100 μL) was added, followed by 5% CO2. 2The mixture was incubated at 37°C for 24 hours in an incubator. As a control, 100 μL of DMEM (containing 10% FBS) without Dox added was added, and incubated in the same manner. After incubation, the culture supernatant was removed, the cells were washed with PBS, 80 μL of Hoechst 33342 solution (10 μg / mL) was added, and the mixture was incubated at 25°C for 10 minutes. After incubation, the Hoechst 33342 solution was removed, the cells were washed with PBS, 100 μL of DMEM (containing 10% FBS) was added, and observation was performed with a confocal scanning microscope (CLSM, FLUOVIEW FV10i, manufactured by Olympus Corporation).
[0194] FIG. 4 shows the transmitted light image, blue fluorescence (Hoechst) image, green fluorescence image, and red fluorescence image captured for each cell. Both the green fluorescence image and the red fluorescence image are images in which Dox-derived fluorescence was detected.
[0195] Based on the intracellular fluorescence intensity in the acquired microscope images, the amount of Dox introduced into the cells was measured (n=60). The average value of the intracellular Dox amount (relative amount) was calculated. The results are shown in Table 6. The p-values in the table represent the significance probability relative to control cells.
[0196]
[0197] (Cytotoxicity evaluation of Dox-encapsulating virus capsid) It was investigated whether Dox taken into cells by the Dox-encapsulating virus capsid exerts a medicinal effect. HepG2 cells were adjusted to 2.0×10 4 cells / well, seeded at 100 μL per well in a 96-well plate, and cultured in a CO 2 incubator at 37°C for 24 hours. Next, after removing the supernatant from the wells of the plate, a solution prepared by adding Dox (final concentration 960 nM), Dox-encapsulating virus capsid (2.4 μM β-annulus, 1.6 μM β-annulus-PFE, 960 nM Dox), or Dox-non-encapsulating virus capsid (2.4 μM β-annulus, 1.6 μM β-annulus-PFE) to 100 μL of DMEM (containing 10% FBS) solution was added, and 5% CO 2The cells were incubated in an incubator at 37°C for 24 hours. As a control, 100 μL of DMEM (containing 10% FBS) without Dox was added and incubated in the same manner. After incubation, the culture supernatant was removed, and cell viability (%) was calculated using MTT assay reagents.
[0198]
[0199] Table 7 shows the results of measuring the cell viability of each cell type. The p-values in the table represent the significance level compared to control cells. Cells that incorporated Dox-encapsulated viral capsids had a significantly lower viability than cells that incorporated Dox without encapsulation.
[0200] Next, Dox-encapsulated virus capsids were introduced into cells at various concentrations, and their cytotoxicity was evaluated. Specifically, HepG2 cells were incubated in the following solutions for 24 hours, and cell viability was measured using an MTT assay.
[0201] Solution A1: DMEM (containing 10% FBS). Solution A2: A solution containing 20 μM β-annulus and 5 μM TMR-β-annulus in DMEM (containing 10% FBS). Solution B1: A solution containing Dox (480 nM) in DMEM (containing 10% FBS). Solution B2: A solution containing Dox-encapsulated viral capsid (1.2 μM β-annulus, 0.8 μM β-annulus-PFE, Dox 480 nM) in DMEM (containing 10% FBS). Solution C1: A solution containing Dox (720 nM) in DMEM (containing 10% FBS). Solution C2: A solution containing DMEM (containing 10% FBS) with Dox encapsulated viral capsid (1.8 μM β-annulus, 1.2 μM β-annulus-PFE, Dox 720 nM). Solution D1: A solution containing DMEM (containing 10% FBS) with Dox (960 nM). Solution D2: A solution containing DMEM (containing 10% FBS) with Dox encapsulated viral capsid (2.4 μM β-annulus, 1.6 μM β-annulus-PFE, Dox 960 nM). Solution E1: A solution containing DMEM (containing 10% FBS) with Dox (1440 nM). Solution E2: A solution containing DMEM (containing 10% FBS) with Dox encapsulated viral capsid (3.6 μM β-annulus, 2.4 μM β-annulus-PFE, Dox 1440 nM). Solution F1: A solution containing DMEM (containing 10% FBS) with Dox (1920 nM). Solution F2: A solution containing DMEM (containing 10% FBS) with Dox encapsulated viral capsid (4.8 μM β-annulus, 3.2 μM β-annulus-PFE, Dox 1920 nM). Solution G1: A solution containing DMEM (containing 10% FBS) with Dox (2400 nM). Solution G2: A solution containing DMEM (10% FBS) with Dox encapsulated virus capsid (6.0 μM β-annulus, 4.0 μM β-annulus-PFE, Dox 2400 nM). Solution H1: A solution containing DMEM (10% FBS) with Dox (3600 nM).Solution H2: A solution containing DMEM (containing 10% FBS) with Dox encapsulated viral capsid (9.0 μM β-annulus, 6.0 μM β-annulus-PFE, Dox 3600 nM). Solution I1: A solution containing DMEM (containing 10% FBS) with Dox (4800 nM). Solution I2: A solution containing DMEM (containing 10% FBS) with Dox encapsulated viral capsid (12.0 μM β-annulus, 8.0 μM β-annulus-PFE, Dox 4800 nM).
[0202]
[0203] Table 8 shows the results of measuring the cell viability of each cell type. When comparing cells with the same Dox concentration, cells that had taken up Dox-encapsulated viral capsids had a lower viability than cells that had taken up Dox without encapsulation. These results indicate that Dox can be taken up into cells and exert its effects more efficiently by encapsulating it in a viral capsid.
[0204] [Reference Example 5] The critical association concentration (CAC) was investigated when β-annular peptide and PFE-modified β-annular peptide were self-assembled to form an artificial viral capsid. The viral capsid containing the PFE-modified β-annular peptide was formed using the β-annular and β-annular-PFE used in Reference Example 1.
[0205] A viral capsid containing a PFE-modified β-annular peptide with the composition shown in Table 9 was formed in the same manner as in Reference Example 2.
[0206]
[0207] Next, the CAC (Capsule Acquisition Coefficient) was investigated when β-annulus and β-annulus-PFE self-assembled to form an artificial viral capsid. A β-annulus aqueous solution (500 μM β-annulus) (0.9 μL) and a β-annulus-PFE / DMSO solution (500 μM β-annulus-PFE) (0.6 μL) were placed in 1.5 mL tubes, and the solvent was removed by lyophilization. Then, phosphate buffer (10 mM, pH 7.4) was added, the mixture was vortexed for 30 seconds, followed by ultrasonic irradiation for 5 minutes, and then allowed to stand at 25°C for 40 minutes. The resulting solution (25 μM) was diluted with the aforementioned phosphate buffer to prepare solutions ranging from 1 to 20 μM. Each solution of each concentration was vortexed for 30 seconds, followed by ultrasonic irradiation for 5 minutes, and then allowed to stand at 25°C for 40 minutes. DLS (Digital Lysis Spectroscopy) measurements were then performed on each solution at 25°C. The measurement results are shown in Figure 5. As shown in Figure 5, it was observed that the particle size of the formed viral capsid tended to increase as the β-annular-PFE content increased.
[0208] In DLS measurements, the mean count rate was defined as the average of 10 count rate measurements. The mean count rate results for each solution are shown in Figure 6. In Figure 6, upward-sloping data points of 2 μM or more were approximated by a linear method using the least squares method, and the concentration at the intersection with the horizontal portion of the line below 2 μM was defined as the CAC. As a result, the CAC of the viral capsid formed by the self-assembly of β-annulus and β-annulus-PFE was 2.0 μM. This is a very low concentration compared to the CAC of β-annulus alone (25 μM). Since self-assembly is easier when the CAC is low, it was found that using β-annulus modified with fluorine-containing alkyl ether groups such as β-annulus-PFE as a subunit makes self-assembly easier and viral capsid formation easier. Viral capsids with low CAC are more stable and may be able to maintain the capsid for a longer period when administered in vivo. From this perspective as well, the artificial viral capsid according to the present invention is very promising as a DDS carrier.
[0209] [Reference Example 6] The particle size of PFE-modified β-annular virus capsids and mRNA-encapsulated PFE-modified β-annular virus capsids was measured by DLS measurement, and the change in particle size due to the presence or absence of mRNA was confirmed. Unmodified mRNA encoding the fluorescent protein mCherry (mCherry mRNA: 945 nucleotides long) (Funakoshi / OZBIOSCIENCES) was used as the mRNA.
[0210] (1) Formation of PFE-modified β-annulus virus capsid As raw materials for the virus capsid, β-annulus, β-annulus-PFE synthesized in Reference Example 1, and dT 20 -SS-β-annulus (a β-annulus in which poly(T)DNA (DNA with 20 T units linked together) is linked to the N-terminus by an SS bond) was used. A 1.0 mM β-annulus-PFE / DMSO solution (0.4 μL), a 500 μM β-annulus aqueous solution (1.02 μL), and 10 μM dT were used. 20 An aqueous solution of SS-β-annulus virus (8.8 μL) was placed in a 1.5 mL tube, and then 30 μL of water (Nuclease-free Water, NEW ENGLAND BioLabs) was added. The solvent was then removed by freeze-drying. Next, 40 μL of phosphate buffer (10 mM, pH 7.4) was added to the tube, and the mixture was slowly pipetted to form PFE-modified β-annulus virus capsids. The solution containing the PFE-modified β-annulus virus capsids (25 μM) after pipetting was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0211] (2) Formation of mRNA-encapsulated PFE-modified β-annular virus capsids The mRNA-encapsulated PFE-modified β-annular virus capsids were formed in the same manner as in (1) above, except that the phosphate buffer (10 mM, pH 7.4) (40 μL) added to the peptide powder in the 1.5 mL tube after lyophilization was changed to a mixture of 1.1 μM mCherry mRNA aqueous solution (16 μL) and phosphate buffer (10 mM, pH 7.4) (24 μL). The solution (25 μM) containing the mRNA-encapsulated PFE-modified β-annular virus capsids after pipetting was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0212] (3) Formation of β-annulus virus capsid As raw materials for the virus capsid, β-annulus and dT 20 -SS-β-annulus was used. A 500 μM β-annulus aqueous solution (1.82 μL) and a 10 μM dT 20 An aqueous solution of SS-β-annulus (8.8 μL) was placed in a 1.5 mL tube, and then 30 μL of water (Nuclease-free Water, NEW ENGLAND BioLabs) was added. The solvent was then removed by freeze-drying. Next, 40 μL of phosphate buffer (10 mM, pH 7.4) was added to the tube, and the mixture was slowly pipetted to form the β-annulus virus capsid. The solution containing the β-annulus virus capsid (25 μM) after pipetting was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0213] (4) Formation of mRNA-encapsulated β-annular virus capsids The mRNA-encapsulated β-annular virus capsids were formed in the same manner as in (3) above, except that the phosphate buffer (10 mM, pH 7.4) (40 μL) added to the peptide powder in the 1.5 mL tube after lyophilization was changed to a mixture of 1.1 μM mCherry mRNA aqueous solution (16 μL) and phosphate buffer (10 mM, pH 7.4) (24 μL). The solution (25 μM) containing the mRNA-encapsulated β-annular virus capsids after pipetting was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0214]
[0215] From the particle size distribution obtained by DLS measurement, the particle size (R) of each β-annular virus capsid was determined. H The particle size (nm) was determined. The results are shown in Table 10. The particle size of the β-annular virus capsid was approximately 77 nm, while the particle size of the PFE-modified β-annular virus capsid was approximately 98 nm, indicating that the particle size was increased by about 20 nm due to PFE modification. Furthermore, the particle size of the mRNA-encapsulated β-annular virus capsid was approximately 106 nm, increasing by about 30 nm due to mRNA encapsulation. On the other hand, the particle size of the mRNA-encapsulated PFE-modified β-annular virus capsid was approximately 221 nm, nearly doubling in size due to mRNA encapsulation.
[0216] Next, to investigate the relationship between the size and concentration of the viral capsid, the particle size (R) of mRNA-encapsulated PFE-modified β-annular viral capsids at various concentrations was measured. H I investigated ).
[0217] (5) Formation of 15 μM mRNA-encapsulated PFE-modified β-annular virus capsid A 15 μM mRNA-encapsulated PFE-modified β-annular virus capsid solution was prepared by adding 10 μL of phosphate buffer (10 mM, pH 7.4) to 15 μL of the 25 μM solution containing the mRNA-encapsulated PFE-modified β-annular virus capsid formed in (2) above, and slowly pipetting the mixture. The solution was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0218] (6) Formation of 10 μM mRNA-encapsulated PFE-modified β-annular virus capsid A 10 μM mRNA-encapsulated PFE-modified β-annular virus capsid solution was prepared by adding 15 μL of phosphate buffer (10 mM, pH 7.4) to 10 μL of the solution (25 μM) containing the mRNA-encapsulated PFE-modified β-annular virus capsid formed in (2) above, and slowly pipetting. The solution was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0219] (7) Formation of 5 μM mRNA-encapsulated PFE-modified β-annular virus capsid A 5 μM mRNA-encapsulated PFE-modified β-annular virus capsid solution was prepared by slowly pipetting 5 μL of the solution (25 μM) containing the mRNA-encapsulated PFE-modified β-annular virus capsid formed in (2) above, adding 20 μL of phosphate buffer (10 mM, pH 7.4), and stirring. The solution was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0220] (8) Formation of 2.5 μM mRNA-encapsulated PFE-modified β-annular virus capsid A 2.5 μM mRNA-encapsulated PFE-modified β-annular virus capsid solution was prepared by adding 22.5 μL of phosphate buffer (10 mM, pH 7.4) to 2.5 μL of the 25 μM solution containing the mRNA-encapsulated PFE-modified β-annular virus capsid formed in (2) above, and slowly pipetting. The solution was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0221]
[0222] From the particle size distribution obtained by DLS measurement, the particle size (R) of each β-annular virus capsid was determined. H The particle size (nm) was determined. The results are shown in Table 11. The particle size of all β-annular virus capsids was 200 nm or larger, and in particular, the particle size of the β-annular virus capsids diluted to 2.5–15 μM was 250 nm or larger, and all were of similar magnitude. These results confirm that the particle size does not change even when the virus capsid is diluted to a low concentration after formation.
[0223] [Reference Example 7] mRNA-encapsulated PFE-modified β-annular virus capsids were introduced into HepG2 cells, and intracellular mRNA expression was evaluated by CLSM observation. As controls, mRNA-encapsulated β-annular virus capsids, mRNA alone, and mRNA complexed with the commercially available cationic lipid reagent Lipofectamine were also introduced into HepG2 cells in the same manner, and CLSM observation was performed.
[0224] (1) Formation of mRNA-encapsulated PFE-modified β-annular virus capsid: 1.0 mM β-annular-PFE / DMSO solution (1.0 μL), 500 μM β-annular aqueous solution (2.56 μL), and 30 mM dT 20 7.53 μL of SS-β-annularis aqueous solution was placed in a 1.5 mL tube, and then 80 μL of water (Nuclease-free Water, NEW ENGLAND BioLabs) was added. The solvent was then removed by freeze-drying. Next, 40 μL of 1.1 μM mCherry mRNA aqueous solution was added to the tube, and the mixture was slowly pipetted to form mRNA-encapsulated PFE-modified β-annularis virus capsids. 10% FBS-containing DMEM (60 μL) was added to the solution containing the mRNA-encapsulated PFE-modified β-annularis virus capsids after pipetting, and the mixture was slowly pipetted. The solution containing the mRNA-encapsulated PFE-modified β-annularis virus capsids after pipetting was allowed to stand at 37°C for 30 minutes, and then DLS measurement was performed.
[0225] (2) Formation of mRNA-encapsulated β-annular virus capsid 1.0 mM β-annular-PFE / DMSO solution (1.0 μL), 500 μM β-annular aqueous solution (4.56 μL), and 30 mM dT 20 A 7.35 μL aqueous solution of SS-β-annulus virus was placed in a 1.5 mL tube, and then 40 μL of water (Nuclease-free Water, NEW ENGLAND BioLabs) was added. The solvent was then removed by freeze-drying. Next, 40 μL of 1.1 μM mCherry mRNA aqueous solution was added to the tube, and the mixture was slowly pipetted to form mRNA-encapsulated β-annulus virus capsids. 10% FBS-containing DMEM (60 μL) was added to the solution containing the mRNA-encapsulated β-annulus virus capsids after pipetting, and the mixture was slowly pipetted.
[0226] (3) Formation of Lipo-complexed mRNA The complexing of mRNA with Lipofectamine was performed according to the protocol provided by the manufacturer and distributor of the Lipofectamine reagent (Lipofectamine MessengerMAX Reagent, manufactured by Invitrogen). Specifically, Opti-MEM (125 μL) and Lipofectamine reagent (7.5 μL) were placed in a 1.5 mL tube and mixed with a vortex mixer for 3 seconds. A mixture of 1.1 μM mCherry mRNA aqueous solution (40 μL) and Opti-MEM (200 μL) was added to the 1.5 mL tube and incubated at 25°C for 5 minutes to prepare a solution containing mRNA complexed with the Lipofectamine reagent (Lipo-complexed mRNA solution).
[0227] (4) Introduction into HepG2 cells and CLSM observation 100 μL of HepG2 cells (4.0 × 10 4 After immobilizing the cells on a dish, 100 μL each of mRNA-encapsulated PFE-modified β-annular virus capsid, mRNA-encapsulated β-annular virus capsid, Lipo-complexed mRNA, or mRNA alone is added, and 5% CO2 is added. 2 The culture supernatant was incubated at 37°C for 3 hours in an incubator. The culture supernatant was removed from the dish, washed with PBS, and Hoechst 33342 solution (Hoechst 33342 dissolved in DMEM (containing 10% FBS) to a concentration of 1 μg / mL, 80 μL) was added, followed by 5% CO2. 2 The samples were incubated at 37°C for 10 minutes in an incubator. After incubation, the supernatant was removed, washed with PBS, and 100 μL of DMEM (containing 10% FBS) was added. The samples were then observed using a confocal scanning microscope (CLSM, FLUOVIEW FV10i, Olympus).
[0228] Microscopic images of each cell are shown in Figure 7. In cells into which mRNA-encapsulated PFE-modified β-annular virus capsids were introduced, a large amount of mCherry-derived red fluorescence was observed throughout the cell. On the other hand, in cells into which mRNA-encapsulated β-annular virus capsids were introduced, almost no mCherry-derived red fluorescence was observed. These results suggest that PFE modification of β-annular virus capsids improves the efficiency of mRNA delivery into cells and intracellular expression. Furthermore, in cells with mRNA alone (negative control), almost no mCherry-derived fluorescence was observed, while in cells into which Lipo-complexed mRNA (positive control) was introduced, red fluorescence was observed in some cells.
[0229] Next, the intracellular delivery efficiency and expression efficiency of mRNA were evaluated by quantifying the fluorescence intensity derived from mCherry within cells. The fluorescence intensity derived from mCherry within cells was normalized by subtracting the extracellular fluorescence intensity from the intracellular fluorescence intensity using the image analysis software "Image J". The average values (n=60) of the TMR fluorescence intensity detected from each cell are shown in Table 12. As a result, the fluorescence intensity derived from mCherry was highest in cells into which mRNA-encapsulated PFE-modified β-annular virus capsids were introduced, approximately 4.3 times higher than in cells into which Lipo-complexed mRNA was introduced, and approximately 6.3 times higher than in cells into which mRNA-encapsulated β-annular virus capsids were introduced. These results suggest that PFE modification of β-annular virus capsids improves the intracellular delivery efficiency of mRNA and may lead to more efficient expression.
[0230]
[0231] [Reference Example 8] Perfluoroalkyl ether group (-CH) as a fluorine-containing peptide 2 -CF 2 -O-CF 2 -O-CF 2 -O-CF 2 -O-CF 3Using the fluorine-containing peptide linked to the β-annular peptide, an artificial viral capsid was formed using the β-annular peptide and the TMR-β-annular peptide used in Reference Example 1.
[0232] <Synthesis of β-annulus-PFE2>
[0233]
[0234] A fluorine-containing peptide (hereinafter sometimes referred to as "PFE2") (1.1 mg), in which a perfluoroalkyl ether group was linked to the carboxyl group of the side chain of the aspartic acid residue of a tetrapeptide (CANF: SEQ ID NO: 3) with a divalent group obtained by removing one hydrogen atom from the amino group and one hydrogen atom from the hydroxyl group of 4-aminophenol, was dissolved in DMF (50 μL) and added to a solution of β-Annulus-PEG2-maleimide (1 mg) in another DMF (50 μL). DIPEA (10 μL) was added to the resulting mixture and stirred at 25°C for 12 hours (final concentrations: β-Annulus-PEG2-maleimide 3.67 mM, PFE2 11.24 mM). The reaction solution was purified by reverse-phase HPLC (isolation yield 35%) and identified by MALDI-TOF-MS.
[0235] In RP-HPLC, a peak of the purified product was observed around 52 minutes. Analysis of the purified product at this peak using MALDI-TOF-MS revealed a β-annular-PFE m / z value of 3547.1 [M+H]. + (The calculated value was 3547.1.)
[0236] <Formation of β-Annulus-PFE2 Modified Artificial Virus Capsid> First, 20 μL of a 50 μM β-Annulus-PFE2 / DMSO solution was mixed with 30 μL of ultrapure water, and the mixed solvent was removed by freeze-drying. The resulting residue was resuspended in 20 μL of 10 mM phosphate buffer (pH 7.4), followed by the addition of 30 μL of a 50 μM β-Annulus solution and 50 μL of 10 mM phosphate buffer (pH 7.4) (the final concentrations in the 10 mM phosphate buffer (pH 7.4) were 10 μM of β-Annulus-PFE2 and 15 μM of β-Annulus). The resulting mixture was vortexed for 30 seconds, and then sonicated for 5 minutes to form a capsid. After sonication, the capsid was allowed to stand at 37°C for 40 minutes. The particle size of the obtained β-annular-PFE2 modified artificial viral capsid was measured by DLS and found to be 115 ± 30 nm (PDI = 0.3).
[0237] <Formation of TMR-labeled β-annulus-PFE2 modified artificial viral capsid> 20 μL of 50 μM β-annulus-PFE2 / DMSO solution was mixed with 30 μL of ultrapure water, and the mixed solvent was removed by freeze-drying. The resulting residue was resuspended in 10 mM phosphate buffer (pH 7.4, 20 μL), followed by the addition of 30 μM β-annulus solution, 10 μM TMR-β-annulus solution, and 50 μL of 10 mM phosphate buffer (pH 7.4) (the final concentrations in the 10 mM phosphate buffer (pH 7.4) were 10 μM β-annulus-PFE2, 10 μM β-annulus, and 5 μM TMR-β-annulus). The resulting mixture was vortexed for 30 seconds, and then sonicated for 5 minutes to form a capsid. The capsid was subjected to sonication and then allowed to stand at 37°C for 40 minutes. The particle size of the obtained TMR-labeled β-annular-PFE2 modified artificial viral capsid was measured by DLS and found to be 125 ± 40 nm (PDI = 0.35).
[0238] <Formation of TMR-labeled β-annulus artificial virus capsid> A mixture of 50 μM β-annulus solution (40 μL), 50 μM TMR-β-annulus solution (10 μL), and 10 mM phosphate buffer (pH 7.4, 50 μL) was prepared (the final concentrations in the 10 mM phosphate buffer (pH 7.4) were 20 μM β-annulus and 5 μM TMR-β-annulus). The resulting mixture was vortexed for 30 seconds and then sonicated for 5 minutes to form a capsid. After sonication, the capsid was allowed to stand at 37°C for 40 minutes.
[0239] <Intracellular transport of TMR-labeled β-annular-PFE2 modified artificial viral capsids> The uptake of TMR-labeled β-annular-PFE2 modified artificial viral capsids into HepG2 cells was investigated. Specifically, except for using two types of solutions (solution A or B) below for cell culture, the procedure was the same as in Reference Example 1, <Intracellular transport of β-annular-PFE modified artificial viral capsids>, and cells that had taken up each TMR-labeled artificial viral capsid were observed using a confocal scanning microscope after nuclear staining with Hoechst 33342.
[0240] Solution A: A solution containing 20 μM β-annulus and 5 μM TMR-β-annulus in DMEM (containing 10% FBS). Solution B: A solution containing 10 μM β-annulus, 10 μM β-annulus-PFE2 and 5 μM TMR-β-annulus in DMEM (containing 10% FBS).
[0241] Figure 8 shows microscopic images of HepG2 cells cultured in each solution. While fluorescence from TMR was detected, it was weak in cells cultured in solution A, which contains a TMR-labeled β-annulus artificial viral capsid. On the other hand, strong fluorescence from TMR was observed in cells cultured in solution B, which contains a TMR-labeled β-annulus-PFE2 modified artificial viral capsid.
[0242] The fluorescence intensity of intracellular TMR in the acquired microscopic images was normalized by subtracting the extracellular fluorescence intensity from the intracellular fluorescence intensity using the image analysis software "Image J". The average values of the TMR fluorescence intensity detected from each cell (n=60) are shown in Table 13.
[0243]
[0244] [Example 1] An experiment was conducted to improve the targeting of cancer cells by forming an artificial viral capsid by self-assembling β-annular peptide and a subunit in which folic acid was bound to the β-annular peptide.
[0245] (1) Synthesis of folic acid-PySS (pyridyl disulfide)
[0246]
[0247] Folic acid (20 mg) was dissolved in anhydrous DMSO (2.0 mL) at 40°C under a nitrogen atmosphere. DCC (13.1 mg) and N-hydroxysuccinimide (7.3 mg) were added to the resulting mixture, and the mixture was stirred in the dark at 37°C for 18 hours. The resulting mixture was filtered using a syringe, and 2 equivalents of dry pyridine were added. Immediately afterward, 2-(pyridyldithio)ethylamine hydrochloride (12.1 mg) dissolved in DMSO (500 μL) was added, and the mixture was stirred for 16 hours. The resulting reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS. The isolation yield was 50% (13.8 mg). Details of the MALDI-TOF-MS measurement method and purification conditions are as described in <MALDI-TOF-MS> above.
[0248] In reverse-phase HPLC, the peak of the purified product was observed at approximately 26 minutes. Analysis of the purified product at this peak using MALDI-TOF-MS revealed a folic acid-PySS m / z value of 632.24 [M + Na]. + (The calculated value was 632.15.)
[0249] (2) Synthesis of β-annulus-FA
[0250]
[0251] β-Annulus-Cys (4.0 mg) was dissolved in DMSO (500 μL) and added to a DMSO solution of folic acid-PySS (1.3 mg / 500 μL DMSO). The resulting mixture was then stirred at 37°C for 36 hours. The resulting reaction solution was purified by reverse-phase HPLC and identified by MALDI-TOF-MS.
[0252] In reverse-phase HPLC, the peak of the purified product was observed at approximately 32 minutes. Analysis of the purified product at this peak by MALDI-TOF-MS revealed a β-annulus-FA m / z value of 2850.13 [M+H]. + (The calculated value was 2850.14.)
[0253] (3) Formation of TMR-labeled β-annulus-FA / PFE-modified artificial viral capsids TMR-labeled β-annulus-FA / PFE-modified artificial viral capsids having different subunit compositions were formed, and the effect of the subunit composition on the cell membrane permeability of the viral capsid was investigated. Specifically, TMR-labeled β-annulus-FA / PFE-modified artificial viral capsids were formed using β-annulus-FA prepared in (2) above, and β-annulus, TMR-β-annulus, and β-annulus-PFE used in Reference Example 1.
[0254] The raw material solutions for the β-annulus virus capsid were prepared by mixing β-annulus solution (100.0 μM, solvent: nuclease-free water), TMR-β-annulus solution (50.0 μM, solvent: nuclease-free water), β-annulus-PFE (100.0 μM, solvent: DMSO), β-annulus-FA (400.0 μM, solvent: nuclease-free water and 2% DMSO), and nuclease-free water so that the final concentrations of β-annulus, TMR-β-annulus, β-annulus-PFE, and β-annulus-FA were as shown in Table 14. The raw material solution was freeze-dried to remove the solvent, then resuspended in DMEM (60.0 μL, 10.0% FBS), mixed with PBS (pH 7.5, 40.0 μL), and stirred at 37°C for 40 minutes to induce self-assembly of the viral capsid in the solution. The subunit ratio of the formed viral capsid was approximately equal to the composition ratio of the raw material solution.
[0255]
[0256] (4) Intracellular transport of TMR-labeled β-annulus-FA / PFE-modified artificial viral capsids First, HeLa cells, HepG2 cells, and HEK293T cells are each placed in single-well glass-bottom dishes in 3.2 × 10⁻⁶ units. 4 Add enough cells per well, then add 5% CO2. 2 The cells were incubated in an incubator at 37°C for 24 hours. Then, the viral capsids formed in test groups 8-4 and 8-9 were added to the culture medium of HeLa cells, HepG2 cells, or HEK293T cells, and 5% CO2 was added. 2 The cells were incubated in an incubator at 37°C for 12 hours. After incubation, the culture medium was removed, washed with PBS, and the cells were stained with Hoechst 33342 before being observed with a confocal scanning microscope. The TMR-derived fluorescence intensity was normalized by subtracting the extracellular fluorescence intensity from the intracellular fluorescence intensity using Image J, as in Reference Example 1.
[0257] The acquired microscopic images are shown in Figures 8 and 9, and the average TMR-derived fluorescence intensity (n=60) is shown in Table 15. The control group consisted of HEK293T cells cultured under the same conditions except for the absence of viral capsid.
[0258]
[0259] As shown in Figures 8 and 9 and Table 15, in test groups 8-4 and 8-9, stronger fluorescence intensity was observed compared to the control, confirming that these viral capsids were delivered into cells. In particular, the viral capsid in test group 8-4, which contained β-annulus-FA, showed improved TMR fluorescence intensity in HeLa cells compared to test group 8-9, which did not contain β-annulus-FA, indicating specific delivery to HeLa cells. This was thought to be because the viral capsid containing β-annulus-FA specifically bound to the folate receptor (FR), which is highly expressed in HeLa cells. Furthermore, these results suggest that ligands consisting of small molecules other than folate may also have increased targeting to specific cancer cells by attaching the β-annulus peptide to a portion that does not inhibit receptor binding.
[0260] Next, the viral capsids formed in test groups 8-1 to 8-9 were added to the culture medium of HeLa cells, incubated and stained under the same conditions, and observed using a laser scanning microscope and measured the TMR-derived fluorescence intensity using the same methods. The average values of the TMR fluorescence intensity detected from each cell (n=60) are shown in Table 16.
[0261]
[0262] (5) Particle size of β-Annulus-FA / PFE modified artificial virus capsid The particle size of the virus capsids formed in test groups 8-1 to 8-9 was measured using the method described in <Measurement of particle size by dynamic light scattering (DLS)> above. The results are shown in Table 16. As shown in Table 16, the TMR fluorescence intensity in HeLa cells changed depending on the β-Annulus-FA content ratio in the capsid, indicating that the deliverability to HeLa cells differed. In particular, the TMR fluorescence intensity showed a maximum value when the β-Annulus-FA content ratio in the capsid was 20 mol% (test group 8-4), indicating the greatest deliverability.
[0263] [Example 2] An experiment was conducted to improve the targeting of cancer cells by forming an artificial viral capsid by self-assembling a β-annular peptide and a subunit in which a cRGD peptide was bound to the β-annular peptide.
[0264] <Synthesis of β-annulus-cRGD>
[0265]
[0266] β-annulus-cRGD was synthesized by Michael addition reaction of β-annulus-PEG2-maleimide, used in Reference Example 1, to the thiol group of the Cys side chain of the cRGD peptide. First, 0.30 mg of cRGD peptide (Funakoshi Co., Ltd.) was added to 592.3 μL of TCEP solution (a solution of 1 mM TCEP (tris(2-carboxyethyl)phosphine hydrochloride) dissolved in 10 mM phosphate buffer (pH 7.4)) and allowed to stand at room temperature for 30 minutes. To the obtained cRGD peptide solution, β-annulus-PEG2-maleimide solution (a solution of β-annulus-PEG2-maleimide (0.70 mg) dissolved in DMF (197.4 μL)) was added and allowed to stand at 37°C for 3 hours. The resulting reaction solution was purified by reverse-phase HPLC (theoretical yield 0.26 μmol, actual yield 0.074 μmol, yield 28%) and identified by MALDI-TOF-MS.
[0267] In reverse-phase HPLC, the peak of the purified product was observed at approximately 34.1 minutes. Analysis of the purified product at this peak by MALDI-TOF-MS revealed that the m / z value of β-annular-cRGD was 3239 (calculated value 3239).
[0268] <Formation of TMR-labeled β-annulus-cRGD-modified artificial viral capsids> Viral capsids with different subunit compositions were formed using β-annulus-cRGD and TMR-β-annulus used in Reference Example 1. 13.5 μL of 100 μM β-annulus-cRGD aqueous solution and 1.5 μL of 100 μM TMR-β-annulus aqueous solution were placed in separate 1.5 mL tubes, and ultrapure water (20 μL) was added to each, after which the solvent was removed by freeze-drying. Next, 28.5 μL of 10 mM phosphate buffer (pH 7.4) and 1.5 μL of DMSO were placed in a tube containing lyophilized β-annulus-cRGD and dissolved. The entire resulting solution was then placed in a tube containing lyophilized TMR-β-annulus to prepare a raw material solution (50 μM) containing β-annulus-cRGD and TMR-β-annulus in a molar ratio of 9:1. Furthermore, this solution was diluted with 10 mM phosphate buffer (pH 7.4) containing 5% DMSO to prepare solutions of 25 μM, 10 μM, 5 μM, and 2.5 μM. Each solution was vortexed for 30 seconds, then subjected to ultrasonic irradiation for 5 minutes, and subsequently allowed to stand at 25°C for 40 minutes. After that, the solutions were filtered through a syringe filter (0.22 μm) to obtain artificial viral capsids with a particle size of approximately 150 nm.
[0269]
[0270] <Intracellular transport of TMR-labeled β-annular-cRGD-modified artificial viral capsids> The uptake of TMR-labeled β-annular-cRGD-modified artificial viral capsids into HepG2 cells was investigated. Specifically, except for using the following two solutions (Solution A or B) for cell culture, the procedure was the same as in Reference Example 1, <Intracellular transport of β-annular-PFE-modified artificial viral capsids>, and cells that had taken up each TMR-labeled artificial viral capsid were observed with a confocal scanning microscope after nuclear staining with Hoechst 33342. The following solutions were used after being treated with sonication for 5 minutes and then allowed to stand at 25°C for 30 minutes.
[0271] Solution A: A solution containing 45 μM β-annulus and 5 μM TMR-β-annulus in DMEM. Solution B: A solution containing 45 μM β-annulus-cRGD and 5 μM TMR-β-annulus in DMEM.
[0272] Figure 11 shows microscopic images of HepG2 cells cultured in each solution. Cells cultured in solution A, which contained a TMR-labeled β-annulus artificial viral capsid, showed almost no fluorescence from TMR within the cells. On the other hand, cells cultured in solution B, which contained a TMR-labeled β-annulus-cRGD-modified artificial viral capsid, showed strong fluorescence from TMR within the cells, suggesting that the viral capsid had been taken up into the cells. These results indicate that modifying cRGD promotes the intracellular uptake of the viral capsid.
[0273] The fluorescence intensity of intracellular TMR in the acquired microscopic images was normalized by subtracting the extracellular fluorescence intensity from the intracellular fluorescence intensity using the image analysis software "Image J". The average values of the TMR fluorescence intensity detected from each cell (n=60) are shown in Table 18.
[0274]
[0275] <Inhibition of intracellular delivery of cRGD-modified artificial viral capsid by anti-integrin antibodies> To investigate whether TMR-labeled β-annular-cRGD-modified artificial viral capsid is taken up into cells via αvβ3 and αvβ5 integrins, TMR-labeled β-annular-cRGD-modified artificial viral capsid was added to HepG2 cells pre-treated with anti-integrin antibodies, and the amount of intracellular uptake was measured. As a control, the same experiment was performed using HepG2 cells that had not been treated with anti-integrin antibodies, and the results were compared.
[0276] As the anti-integrin antibody solution, an equal mixture of CD51 / CD61 (Integrin alpha v beta 3) Monoclonal Antibody (23C6, Functional Grade, eBioscience®) (manufactured by Thermo Fisher SCIENTIFIC) and Anti-Human Integrin alpha V beta 5 MAb (Clone P5H9) (manufactured by Funakoshi Co., Ltd.) was mixed in DMEM to create a solution (20 μg / mL).
[0277] First, we placed HepG2 cells in a single-well glass bottom dish (cell density: 4.0 × 10⁶). 4 Add 100 μL of anti-integrin antibody solution to the cells (per well) and add 5% CO2. 2 The culture supernatant was incubated at 37°C for 1 hour. Afterwards, the culture supernatant was removed, washed with PBS, and then 100 μL of the following solution (Solution A or B) was added, followed by 5% CO2. 2 The cells were incubated in an incubator at 37°C for 3 hours. Then, as in Reference Example 1, the cells containing each TMR-labeled artificial viral capsid were washed with PBS, followed by nuclear staining with Hoechst 33342, and then observed with a confocal scanning microscope. The solutions used were prepared by sonicating for 5 minutes and then allowing them to stand at 25°C for 10 minutes.
[0278] Solution A: A solution containing 45 μM β-annulus and 5 μM TMR-β-annulus in DMEM (containing 10% FBS). Solution B: A solution containing 45 μM β-annulus-cRGD and 5 μM TMR-β-annulus in DMEM (containing 10% FBS).
[0279] Figure 12 shows microscopic images of HepG2 cells cultured in each solution. In cells cultured in solution A, which contains a TMR-labeled β-annulus artificial viral capsid, almost no fluorescence from TMR was detected within the cells, regardless of whether or not the cells were treated with anti-integrin antibodies. On the other hand, when cultured in solution B, which contains a TMR-labeled β-annulus-cRGD-modified artificial viral capsid, strong fluorescence from TMR was observed within the cells in untreated cells, indicating that the viral capsid had been taken up into the cells. Even in cells treated with anti-integrin antibodies, some cells showed fluorescence from TMR within the cells, although to a lesser extent than in untreated cells.
[0280] The fluorescence intensity of intracellular TMR in the acquired microscopic images was normalized by subtracting the extracellular fluorescence intensity from the intracellular fluorescence intensity using the image analysis software "Image J". The average values of the TMR fluorescence intensity detected from each cell (n=60) are shown in Table 19.
[0281]
[0282] As shown in Table 19, in cells that had taken up the TMR-labeled β-annular-cRGD-modified artificial viral capsid, the intracellular fluorescence intensity decreased by approximately 40% after treatment with an anti-integrin antibody. This result confirmed that the cRGD-modified artificial viral capsid was taken up into cells via αvβ3 and αvβ5 integrins. Since intracellular uptake of the TMR-labeled β-annular-cRGD-modified artificial viral capsid was also confirmed in cells after treatment with an anti-integrin antibody, it was suggested that the artificial viral capsid may also be taken up into cells via a pathway independent of αvβ3 and αvβ5 integrins.
Claims
1. An artificial viral capsid formed by the self-assembly of a plurality of subunits, wherein the subunits are β-annular peptides of tomato bushy stunt virus, at least a portion of the subunits constituting the artificial viral capsid is a β-annular peptide modified with a ligand of a receptor specifically expressed on cancer cells, and the ligand-modified β-annular peptide has the ligand linked to its C-terminus via a bivalent linking group.
2. The artificial viral capsid according to claim 1, wherein the ligand is a low molecular weight compound, a peptide, an antibody, or a sugar / sugar derivative.
3. The artificial viral capsid according to claim 1, wherein the ligand is one or more selected from the group consisting of cRGD peptide, EGFR peptide, transferrin, mannose, GalNAc, folic acid, and antibodies.
4. The artificial viral capsid according to claim 1, wherein the ligand is one or more selected from the group consisting of folic acid and cRGD peptide.
5. The artificial viral capsid according to claim 1, wherein the ratio of the number of molecules of β-annular peptide modified with the ligand to the total number of molecules of β-annular peptide constituting the artificial viral capsid is 5 mol% or more.
6. The artificial virus capsid according to claim 1, further comprising a β-annular peptide modified with a fluorine-containing group or a long-chain group, wherein the β-annular peptide modified with a fluorine-containing group has a fluorine-containing peptide containing the fluorine-containing group linked to its terminus via a divalent linking group, and the β-annular peptide modified with a long-chain group has a long-chain modified peptide containing the long-chain group linked to its terminus via a divalent linking group, and the long-chain group is an alkyl group having 8 to 30 carbon atoms that is not substituted with a fluorine atom, or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of an alkyl group having 8 to 30 carbon atoms that is not substituted with a fluorine atom.
7. The artificial virus capsid according to claim 6, wherein the fluorine-containing group is an alkyl group having 1 to 30 carbon atoms substituted with one or more fluorine atoms, or an alkyl group having 2 to 30 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between carbon atoms and one or more hydrogen atoms are substituted with fluorine atoms.
8. The artificial virus capsid according to claim 7, wherein the fluorine-containing group is a group in which one or more ether-bonded oxygen atoms are introduced between carbon atoms of an alkyl group having 2 to 30 carbon atoms, and one or more hydrogen atoms are substituted with fluorine atoms, and the ratio of the number of oxygen atoms to the number of fluorine atoms constituting the fluorine-containing group is 0.05 to 0.
40.
9. The fluorine-containing group is the following general formula (1) [In formula (1), R 11 R is an alkylene group having 1 to 6 carbon atoms, or a branched alkylene group having 1 to 6 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms of the side chain; 12 is an alkylene group having 1 to 6 carbon atoms, or a branched alkylene group having 1 to 6 carbon atoms in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms of the side chain; n 1 n is an integer greater than or equal to 1; 1 If R is an integer greater than or equal to 2, there are multiple R 12 The groups may all be of the same type or may be different from each other; the black circles represent bonding. The group represented by ] is a group in which one or more hydrogen atoms are replaced by fluorine atoms, and the number of oxygen atoms constituting the fluorine-containing group is N O The number of fluorine atoms constituting the fluorine-containing group N F The artificial virus capsid according to claim 7, wherein the value obtained by dividing by is 0.05 to 0.
40.
10. The fluorine-containing group is represented by the following general formula (E1) [wherein, R 21 is a fluorine atom, a perfluoroalkyl group having 1 to 6 carbon atoms, or a perfluoroalkyl group having 1 to 6 carbon atoms in which one or more ether-bonding oxygen atoms are introduced between carbon atoms; a1 is an integer of 1 or more; when a1 is an integer of 2 or more, the plurality of R 21 groups may all be the same type of group, or may be groups different from each other; R 31 and R 32 are each independently a fluorine atom, a hydrogen atom, a perfluoroalkyl group having 1 to 6 carbon atoms, or a perfluoroalkyl group having 1 to 6 carbon atoms in which one or more ether-bonding oxygen atoms are introduced between carbon atoms; b1 is an integer of 1 or more; when b1 is an integer of 2 or more, the plurality of R 31 and R 32 groups may all be the same type of group, or may be groups different from each other; the number of carbon atoms in the formula is 2 to 30; the ratio of the number of oxygen atoms to the number of fluorine atoms in the formula is 0.05 to 0.40; the black dot means a bond.] The artificial virus capsid according to claim 7, which is a group represented by the above.
11. The artificial viral capsid according to claim 6, wherein the fluorine-containing peptide is a peptide in which one to three fluorine-containing groups are directly or indirectly linked to the side chain of at least one amino acid residue.
12. The artificial virus capsid according to claim 1, wherein the divalent linking group is a Bis-maleimide group containing maleimide groups at both ends.
13. The artificial viral capsid according to claim 1, wherein the β-annular peptide has a cysteine residue at or near its C-terminus, and the divalent linking group is linked to a thiol group derived from the cysteine residue.
14. A method for producing an artificial viral capsid by self-assembling a raw material β-annular peptide in a solvent, wherein the raw material β-annular peptide contains a β-annular peptide modified with a ligand of a receptor specifically expressed on cancer cells, the ligand is linked to the C-terminus of the ligand-modified β-annular peptide via a divalent linking group, and the content ratio of the ligand-modified β-annular peptide to the total amount of the raw material β-annular peptide is 5 mol% or more.
15. The β-annular peptide of the raw material further contains a β-annular peptide modified with a fluorine-containing group or a long-chain group, wherein the fluorine-containing group is an alkyl group having 1 to 30 carbon atoms substituted with one or more fluorine atoms, or an alkyl group having 2 to 30 carbon atoms, in which one or more ether-bonded oxygen atoms are introduced between the carbon atoms and one or more hydrogen atoms are substituted with fluorine atoms, the long-chain group is an alkyl group having 8 to 30 carbon atoms not substituted with fluorine atoms, or a group having 1 to 5 ether-bonded oxygen atoms between the carbon atoms of an alkyl group having 8 to 30 carbon atoms not substituted with fluorine atoms, the β-annular peptide modified with the fluorine-containing group has a fluorine-containing peptide containing the fluorine-containing group linked to its terminus via a divalent linking group, and the β-annular peptide modified with the long-chain group has a long-chain modified peptide containing the long-chain group linked to its terminus via a divalent linking group. A method for producing an artificial viral capsid according to claim 14.
16. The method for producing an artificial viral capsid according to claim 15, wherein the content ratio of the β-annular peptide modified with the fluorine-containing group or the long-chain group to the total amount of the β-annular peptide of the raw material is 40 mol% or more.
17. A pharmaceutical composition comprising an artificial viral capsid according to any one of claims 1 to 13.
18. The pharmaceutical composition according to claim 17, for the treatment of cancer.
19. A drug delivery carrier composition comprising an artificial viral capsid according to any one of claims 1 to 13.
